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009 STEMI and PCI Focused Updates
reamble
primary challenge in the development of clinical practice
idelines is keeping pace with the stream of new data on which
commendations are based. In an effort to respond promptly to
w evidence, the American College of Cardiology Foundation/
merican Heart Association (ACCF/AHA) Task Force on
actice Guidelines has created a “focused update” process to
vise the existing guideline recommendations that are affected
evolving data or opinion. Before the initiation of this focused
proach, periodic updates and revisions of existing guidelines
quired up to 3 years to complete. Now, however, new evidence
ill be reviewed in an ongoing fashion to more efficiently
spond to important science and treatment trends that could
ve a major impact on patient outcomes and quality of care.
vidence will be reviewed at least twice a year, and updates will
initiated on an as-needed basis as quickly as possible, while
aintaining the rigorous methodology that the ACCF and AHA
ve developed during their 25 years of partnership.
These updated guideline recommendations reflect a consen-
s of expert opinion after a thorough review primarily of
te-breaking clinical trials identified through a broad-based
tting process as being important to the relevant patient
pulation, as well as a review of other new data deemed to have
impact on patient care (see Section 1.1, Methodology and
vidence Review, for details). This focused update is not intended to
present an update based on a full literature review from the date of
e previous guideline publication. Specific criteria/considerations
r inclusion of new data include the following:
publication in a peer-reviewed journal;
large randomized, placebo-controlled trial(s);
nonrandomized data deemed important on the basis of
results that affect current safety and efficacy assumptions;
strength/weakness of research methodology and findings;
likelihood of additional studies influencing current findings;
impact on current performance measure(s) and/or likeli-
hood of need to develop new performance measure(s); prrequests and requirements for review and update from the
practice community, key stakeholders, and other sources
free of relationships with industry or other potential bias;
number of previous trials showing consistent results; and
need for consistency with a new guideline or guideline revision.
In analyzing the data and developing updated recommen-
tions and supporting text, the focused update writing group
ed evidence-based methodologies developed by the ACCF/
HA Task Force on Practice Guidelines, which are described
sewhere (1).
The schema for classification of recommendations and
vel of evidence is summarized in Table 1, which also
ustrates how the grading system provides an estimate of the
ze of the treatment effect and an estimate of the certainty of
e treatment effect. Note that a recommendation with level
evidence B or C does not imply that the recommendation
weak. Many important clinical questions addressed in
idelines do not lend themselves to clinical trials. Although
ndomized trials may not be available, there may be a very
ear clinical consensus that a particular test or therapy is
eful and effective. Both the classification of recommenda-
ns and level of evidence listed in the focused updates are
sed on consideration of the evidence reviewed in previous
rations of the guideline and the focused update. Of note,
e implications of older studies that have informed recom-
endations but have not been repeated in contemporary
ttings are considered carefully.
The ACCF/AHA practice guidelines address patient popula-
ns (and healthcare providers) residing in North America. As
ch, drugs that are not currently available in North America are
scussed in the text without a specific class of recommendation.
r studies performed in large numbers of subjects outside of
orth America, each writing group reviews the potential impact
different practice patterns and patient populations on the
eatment effect and on the relevance to the ACCF/AHA target
pulation to determine whether the findings should inform a
ecific recommendation.
The ACCF/AHA practice guidelines are intended to assist
althcare providers in clinical decision making by describ-
g a range of generally acceptable approaches for the
agnosis, management, and prevention of specific diseases
conditions. The guidelines attempt to define practices that
eet the needs of most patients in most circumstances. The
timate judgment regarding care of a particular patient must
made by the healthcare provider and patient in light of all
e circumstances presented by that patient. Thus, there are
rcumstances in which deviations from these guidelines may
appropriate. Clinical decision making should consider the
ality and availability of expertise in the area where care is
ovided. These guidelines may be used as the basis for
gulatory or payer decisions, but the ultimate goals are
ality of care and serving the patient’s best interests.
Prescribed courses of treatment in accordance with these
commendations are effective only if they are followed by
e patient. Because a lack of patient adherence may ad-
rsely affect treatment outcomes, healthcare providers
ould engage the patient in active participation with the
escribed treatment.
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2009 Focused Updates: STEMI and PCI Guidelines December 1, 2009:2205–41The ACCF/AHA Task Force on Practice Guidelines makes
ery effort to avoid actual, potential, or perceived conflicts
interest that may arise as a result of industry relationships
personal interests among the writing committee. Specifi-
lly, all members of the writing committee, as well as
viewers of the document, are asked to disclose all such
levant relationships pertaining to the trials and other evi-
nce under consideration (see Appendixes 1, 2, and 3). All
ideline recommendations require a confidential vote by the
riting group and must be approved by a consensus of the
embers voting. Members who recused themselves from
ting are noted on the title page of this document. Members
ust recuse themselves from voting on any recommendations
which their relationships with industry and other entities
ply. Writing group members who did not participate are not
ble 1. Applying Classification of Recommendations and Level
*Data available from clinical trials or registries about the usefulness/efficacy i
yocardial infarction, history of heart failure, and prior aspirin use. A recommend
any important clinical questions addressed in the guidelines do not lend them
a very clear clinical consensus that a particular test or therapy is useful or
†In 2003, the ACCF/AHA Task Force on Practice Guidelines developed a
commendations have been written in full sentences that express a complete
e rest of the document (including headings above sets of recommendations),
rease readers’ comprehension of the guidelines and will allow queries at theted as authors of this focused update. The work of the coriting group was supported exclusively by the ACCF and
HA without commercial support. Writing group members
lunteered their time for this effort.
With the exception of the recommendations presented here,
e full-text guidelines remain current (2,3). Only the recom-
endations from the affected section(s) of the full-text guide-
es are included in this focused update. Recommendations
om any section of a guideline affected by a change are
esented with notation as to whether they are new or have been
odified; however, recommendations that remain unchanged in
ch section are not included in this focused update. When
idence affects recommendations in more than 1 set of guide-
es, those guidelines are updated concurrently whenever
ssible.
The recommendations in this focused update will be
ence
nt subpopulations, such as gender, age, history of diabetes, history of prior
th Level of Evidence B or C does not imply that the recommendation is weak.
o clinical trials. Even though randomized trials are not available, there may
.
suggested phrases to use when writing recommendations. All guideline
, such that a recommendation, even if separated and presented apart from
still convey the full intent of the recommendation. It is hoped that this will
ual recommendation level.of Evid
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December 1, 2009:2205–41 2009 Focused Updates: STEMI and PCI Guidelinescused update or the full-text guidelines are revised. This
cused update is published in the December 1, 2009, issues
the Journal of the American College of Cardiology and
irculation as an update to the full-text guideline, and it is
so posted on the American College of Cardiology (ACC;
ww.acc.org), AHA (my.americanheart.org), and Society for
ardiovascular Angiography and Interventions (SCAI;
ai.org) World Wide Web sites.
Alice K. Jacobs, MD, FACC, FAHA
Chair, ACCF/AHA Task Force on Practice Guidelines
. Introduction
1. Methodology and Evidence Review
ate-breaking clinical trials presented at the 2007 and 2008
nual scientific meetings of the ACC, AHA, Transcatheter
ardiovascular Therapeutics, the European Society of Cardi-
ogy, and the 2009 annual scientific sessions of the ACC
ere reviewed by the standing guideline writing committee
ong with the parent Task Force and other experts to identify
ose trials and other key data that may impact guideline
commendations. On the basis of the criteria/considerations
ted above, recent trial data and other clinical information were
nsidered important enough to prompt a focused update of the
CC/AHA 2004 Guidelines for the Management of Patients
ith ST-Elevation Myocardial Infarction and the ACC/AHA
05 Guidelines for Percutaneous Coronary Intervention, inclu-
ve of their respective 2007 focused updates (2–5).
The ST-elevation myocardial infarction (STEMI) and per-
taneous coronary intervention (PCI) writing groups to-
ther considered the following studies: Two meta-analyses,
Comparison of Abciximab and Small Molecule Glyco-
otein IIb/IIIa Inhibitors in Patients Undergoing Primary
rcutaneous Coronary Intervention,” (6) and “Benefits From
mall Molecule Administration as Compared With Abcix-
ab Among Patients With ST-Segment Elevation Myo-
rdial Infarction Treated With Primary Angioplasty,” (7)
INESSE (Facilitated PCI in Patients With ST-Elevation
yocardial Infarction) (8), the HORIZONS-AMI (Harmoniz-
g Outcomes With Revascularization and Stents in Acute
yocardial Infarction) (9), BRAVE-3 (Bavarian Reperfusion
lternatives Evaluation-3) (10), MULTISTRATEGY (Mul-
entre Evaluation of Single High-Dose Bolus Tirofiban
ersus Abciximab With Sirolimus-Eluting Stent or Bare
etal Stent in Acute Myocardial Infarction Study) (11),
N-TIME 2 (Ongoing Tirofiban in Myocardial Infarction
valuation) (12), TRITON-TIMI 38 (Trial to Assess Im-
ovement in Therapeutic Outcomes by Optimizing Platelet
hibition With Prasugrel–Thrombolysis in Myocardial In-
rction) (13), TRANSFER-AMI (Trial of Routine ANgio-
asty and Stenting after Fibrinolysis to Enhance Reperfusion
Acute Myocardial Infarction) (14), CARESS-in-AMI
ombined Abciximab Reteplase Stent Study in Acute Myo-
rdial Infarction) (15), NICE-SUGAR (Normoglycemia in
tensive Care Evaluation—Survival Using Glucose Algo-
thm Regulation) (16), TAPAS (Thrombus Aspiration during
rcutaneous coronary intervention in Acute myocardial
farction Study) (17), and EXPIRA (Thrombectomy With
xport Catheter in Infarct-Related Artery During Primary shrcutaneous Coronary Intervention) (18). Additionally, the
I writing group considered the CARE (Cardiac Angiogra-
y in Renally Impaired Patients) (19), FAME (Fractional
ow Reserve versus Angiography for Multivessel Evalua-
n) study (20), SYNTAX (Synergy Between Percutaneous
tervention With Taxus and Cardiac Surgery) (21), Early
CS (Early versus Delayed, Provisional Eptifibatide in Acute
oronary Syndromes) (22), and TIMACS (Timing of Inter-
ntion in Patients With Acute Coronary Syndromes) studies
3). When considering the new data for this focused update,
e writing group faced the task of weighing evidence from
udies that had enrolled large numbers of subjects outside
orth America. Although noting that practice patterns and the
gor applied to data collection, as well as the genetic makeup
subjects, may influence the observed magnitude of a
eatment’s effect, the writing group believed the data were
levant to the formulation of recommendations for manage-
ent of STEMI and PCI in North America. The writing group
so notes that the AHA/ACCF and the Heart Rhythm Society
ve published updated recommendations for the standard-
ation and interpretation of the electrocardiogram with a
parate section on acute ischemia/infarction (24).
To provide clinicians with a comprehensive set of data,
henever possible, the exact event rates in various treatment
ms of clinical trials are presented to permit calculation of
e absolute risk difference and number needed to treat
NT) or harm; the relative treatment effects are described
ther as odds ratio, relative risk (RR), or hazard ratio (HR)
pending on the format used in the original publication.
long with all other statistical point estimates, the confidence
terval (CI) for those statistics are added when available.
Consult the full-text or executive summary versions of the
CC/AHA 2004 Guidelines for the Management of Patients
ith ST-Elevation Myocardial Infarction or the ACC/AHA/
AI 2005 Guidelines for Percutaneous Coronary Interven-
n, as well as their respective 2007 focused updates, for
licy on clinical areas not covered by the present focused
date (2–5). Unchanged recommendations from previous
rations of the guidelines are not listed in this document and
main current policy. Individual recommendations updated
this focused update will be incorporated into future
visions of the full-text guidelines.
2. Organization of Committee and Relationships
ith Industry and Other Entities
r this focused update, all members of the 2004 STEMI
ideline, 2007 STEMI focused update, 2005 PCI guideline,
d 2007 PCI focused update writing committees were
vited to participate; those who agreed (referred to as the
09 Focused Update Writing Group) were required to
sclose all relationships with industry and other entities
levant to the data under consideration. The policies used for
lationships with industry were those in effect at the initial
eeting of this committee, which included disclosure of
lationships 12 months prior to initiation and a chair with no
levant relationships except in a situation where more than
e chair is named. In this circumstance, one chair will have
relevant relationships and the other may have relation-ips. Each recommendation required a confidential vote by
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2009 Focused Updates: STEMI and PCI Guidelines December 1, 2009:2205–41e writing group members before and after external review
the document. Any writing group member with a relation-
ip with industry relevant to the recommendation was
cused from voting on that recommendation. The PCI
riting group included 2 representatives from SCAI.
3. Document Review and Approval
his document was reviewed by 3 official reviewers nomi-
ted by the ACCF and 4 official reviewers nominated by the
HA, 1 official reviewer nominated by the SCAI, 6 review-
s from the ACCF Interventional Council, 2 reviewers from
e ACCF Imaging Council, and 22 content reviewers. All
viewer information on relationships with industry and other
tities was collected and distributed to the writing commit-
e and is published in Appendix 3. This document was
proved for publication by the governing bodies of the
CCF, the AHA, and the SCAI (specifically, the PCI portion
the guideline).
TEMI and PCI Focused Update Section
. Recommendations for the Use of
lycoprotein IIb/IIIa Receptor Antagonists
ee Table 2 and Appendix 4.)
1. Glycoprotein IIb/IIIa Receptor Antagonists
considering the use of intravenous glycoprotein (GP)
b/IIIa receptor antagonists for STEMI, the writing group
ted that much of the evidence favoring the use of these
ents was established in the era before dual oral antiplatelet
erapy and largely by placebo-controlled comparisons. Con-
mporary management of STEMI patients involves a com-
ex array of antithrombotics, including dual oral antiplatelet
erapy (aspirin [acetylsalicylic acid; ASA] plus a thienopy-
dine) and an anticoagulant. There is a paucity of trials
equately powered for assessment of clinical end points that
ve reevaluated the current relative role of intravenous GP
b/IIIa receptor antagonists with respect to other pharmacolog-
al therapy in STEMI patients. Accordingly, a reevaluation of
e value of GP IIb/IIIa antagonists in STEMI is appropriate, but
ble 2. Recommendations for the Use of Glycoprotein IIb/IIIa R
04/2005/2007 Recommendations:
04 STEMI Guideline Section 6.3.1.6.8.2.3;
so 2005 PCI Guideline Section 6.2.2 2009 Joint ST
Cla
It is reasonable to start treatment with abciximab
as early as possible before primary PCI (with or
without stenting) in patients with STEMI. (Level of
Evidence: B)
1. It is reasonable t
receptor antagon
tirofiban (11,12)
Level of Evidenc
stenting) in selec
Cla
Treatment with tirofiban or eptifibatide may be
considered before primary PCI (with or without
stenting) in patients with STEMI. (Level of
Evidence: C)
1. The usefulness o
of a preparatory
before their arriv
angiography ande ability to draw definitive conclusions is limited. siAt least 3 trials evaluated GP IIb/IIIa antagonists as
juncts to oral antiplatelet therapy in the setting of primary
I. The findings of these trials question whether GP IIb/IIIa
tagonists provide significant additional benefit to STEMI
tients who have received dual-antiplatelet therapy before
theterization. In the BRAVE-3 study, 800 patients pres-
ting within 24 hours of a STEMI were pretreated with 600
g of clopidogrel and then randomly assigned in a double-
ind manner to receive either abciximab or placebo in the
tensive care unit before being sent for PCI (10). The
imary end point was infarct size measured by single photon
ission computed tomography before hospital discharge. At
days, the composite of death, recurrent myocardial infarc-
n (MI), stroke, or urgent revascularization of the infarct-
lated artery was not significantly different in the 2 groups
bciximab 5%, placebo 3.8%; 95% CI 0.7 to 2.6; P0.4).
here was no significant difference in infarct size or major
eeding.
ON-TIME 2 was a randomized, placebo-controlled, multi-
nter European trial that included 491 patients receiving
gh-dose tirofiban and 493 receiving placebo within a
edian of 76 minutes from onset of symptoms (12). Patients
ceiving high-dose tirofiban (25 mcg/kg bolus followed by
15 mcg/kg per min for 18 hours) at first medical contact
fore transport for primary PCI were also treated with
fractionated heparin (UFH; 5000 U), clopidogrel (600 mg),
d ASA. Patients in the high-dose tirofiban group had
proved ST-segment resolution (primary end point) before
d 1 hour after PCI (P0.003) compared with those receiv-
g placebo (NNT100). However, there was no significant
fference in Thrombolysis In Myocardial Infarction (TIMI)
ade 3 flow or blush grade and no significant difference in
ajor bleeding or minor bleeding. There was no significant
fference in death, recurrent MI, or urgent target-vessel
vascularization (TVR) between the tirofiban and placebo
oups at 30 days (25).
In the HORIZONS-AMI trial (9), patients undergoing
imary PCI for STEMI were randomized to treatment with
FH plus a GP IIb/IIIa receptor antagonist (abciximab or
uble-bolus eptifibatide) or to bivalirudin alone with provi-
r Antagonists
I Focused Update Recommendations Comments
reatment with glycoprotein IIb/IIIa
iximab (9,11) Level of Evidence: A,
f Evidence: B or eptifibatide (6,7,9)
t the time of primary PCI (with or without
ents with STEMI.
Modified recommendation
(class of
recommendation
changed from IIb to IIa
for tirofiban and
eptifibatide).
rotein IIb/IIIa receptor antagonists (as part
cological strategy for patients with STEMI
cardiac catheterization laboratory for
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(text modified; level of
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ial under Section 4, Recommendations for the Use of
renteral Anticoagulants.) Seven hundred fifty-seven of the
61 patients who received UFH received a double bolus of
tifibatide and infusion, whereas 53 of 1661 in the bivaliru-
n arm received eptifibatide. At 30 days, rates of major
eeding and total adverse events were higher among patients
eated with GP IIb/IIIa antagonists and heparin than among
ose given bivalirudin alone.
Two meta-analyses of randomized trials were published
at compared small-molecule GP IIb/IIIa antagonists with
ciximab in STEMI patients undergoing primary PCI (6,7).
each case, there was no statistically significant difference
30-day mortality, reinfarction, or major TIMI bleeding, and
ere was no significant difference in death or reinfarction at
months between groups. There was also no statistically
gnificant difference in postprocedural TIMI flow grade 3 or
-segment resolution. On the basis of these studies, the
esent writing group judged that the totality of evidence
dicates that the various GP IIb/IIIa antagonists demonstrate
milar effectiveness in the setting of primary PCI.
MULTISTRATEGY was an open-label, multicenter, ran-
mized European trial with a 2-by-2 factorial design that
ndomized 745 STEMI patients undergoing primary PCI to
gh-dose bolus tirofiban versus abciximab infusion and
rolimus-eluting stent versus bare-metal stent (BMS) (11).
he prespecified primary end points were the achievement of
% resolution of ST-segment elevation at 90 minutes after
I, powered for noninferiority, and the rate of major adverse
rdiac events (MACE) at 8 months, powered for superiority.
ll patients received ASA at the usual doses, clopidogrel 300
g orally then 75 mg per day, and UFH. There was a similar
te of at least 50% ST-segment resolution at 90 minutes after
imary PCI with abciximab and tirofiban (RR 1.020; 97.5%
I 0.958 to 1.086; P0.001 for noninferiority). Rates of
ACE, including all-cause death, clinical reinfarction, or
VR, and hemorrhagic (major and minor bleeding) compli-
tions were similar. The incidence of severe or moderate
rombocytopenia was more common with abciximab than
ith tirofiban (4.0% versus 0.8%, P0.004).
In an analysis of the predictors of stent thrombosis after
imary PCI in acute MI presented at the 2009 ACC Scien-
ic Sessions, titled “Predictors of Stent Thrombosis After
imary Angioplasty in Acute Myocardial Infarction: The
ORIZONS-AMI Trial,” (69) there was no significant dif-
rence in the 1-year rate of stent thrombosis with the heparin
us GP IIb/IIIa receptor antagonists compared with eptifi-
tide and abciximab (3.6% versus 2.8%, P0.93), which
ggests that eptifibatide has the same impact as abciximab
stent thrombosis incidence.
One investigation, FINESSE, addressed the issue of timing
GP IIb/IIIa antagonist administration. This double-blind,
ndomized, placebo-controlled study of 2453 patients with
EMI explored the use of pre-PCI treatment with a half-
se fibrinolytic agent plus abciximab, pre-PCI abciximab
one, and abciximab at the time of PCI (8). The primary end
int was the composite of death due to all causes, ventricular
brillation that occurred more than 48 hours after random-
ation, cardiogenic shock, and congestive heart failure dur- (Ng the first 90 days after randomization. The results of the
ial are discussed in Section 5.1, Triage and Transfer for PCI.
his trial showed no benefit (and a tendency toward excess
eeding) with prehospital abciximab compared with abcix-
ab at the time of PCI. The writing group concluded there
as no benefit of administration of abciximab before primary
I, alone or in combination with reteplase. On the basis of
is trial and ON-TIME 2, the writing group concluded that
e use of GP IIb/IIIa antagonists before primary PCI is of
certain benefit.
Given the results of the studies cited above, the writing
oup concluded that in the setting of dual-antiplatelet ther-
y with UFH or bivalirudin as the anticoagulant, current
idence indicates that adjunctive use of a GP IIb/IIIa
tagonist can be useful at the time of primary PCI but cannot
recommended as routine therapy. These agents might
ovide more benefit in selective use, for example, for the
tient with a large thrombus burden or for patients who have
t received adequate thienopyridine loading.
. Recommendations for the Use of
ienopyridines
ee Table 3 and Appendix 4.)
1. Thienopyridines
nce the publication of the last guidelines (4,5), evidence has
erged about prasugrel, a thienopyridine that achieves
eater inhibition of platelet aggregation than clopidogrel
7). The pivotal trial for prasugrel, TRITON-TIMI 38,
cused on patients with ACS who were referred for PCI.
TRITON-TIMI 38 randomly assigned 13 608 patients with
oderate- to high-risk ACS, 3534 of whom had STEMI, to
ceive prasugrel (6813 patients received a 60-mg loading
se and a 10-mg daily maintenance dose) or clopidogrel
795 patients received a 300-mg loading dose and a 75-mg
ily maintenance dose) for an average follow-up of 14.5
onths. Aspirin was prescribed within 24 hours of PCI.
linical end points were assessed at 30 and 90 days and then
ery 3 to 15 months (27).
Prasugrel was associated with a significant 2.2% absolute
duction and a 19% relative reduction in the primary
ficacy end point, a composite of the rate of death due to
rdiovascular causes (including arrhythmia, congestive heart
ilure, shock, and sudden or unwitnessed death), nonfatal
I, or nonfatal stroke during the follow-up period. The
imary efficacy end point occurred in 9.9% of patients
ceiving prasugrel and 12.1% of patients receiving clopi-
grel (HR for prasugrel versus clopidogrel 0.81; 95% CI
73 to 0.90; P0.001). A significant reduction in the
imary end point was seen in the prasugrel group by the first
especified time point, which was 3 days (4.7% in the
asugrel group versus 5.6% in the clopidogrel group; HR
82; 95% CI 0.71 to 0.96; P0.01), and persisted throughout
e follow-up period. From Day 3 to the end of the study, the
imary end point had occurred in 5.6% of patients receiving
asugrel and in 6.9% of patients receiving clopidogrel (HR
80; 95% CI 0.70 to 0.93; P0.003). Prasugrel decreased
rdiovascular death, MI, and stroke by 138 events
NT46) (27). The rate of MI with subsequent death due to
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EMI Recommendations PCI Recommendations 2009 Joint STEMI/PCI Focused Update Recommendations
Comments (All Modified
Recommendations Are for
Patients With ACS)
Class I
04 STEMI Guidelines,
ction 7.4.4
2007 PCI Update, Table 14
For patients who have undergone
diagnostic cardiac catheterization
and for whom PCI is planned,
clopidogrel should be started and
continued for at least 1 month
after bare metal stent
implantation and for several
months after drug-eluting stent
implantation (3 months for
sirolimus, 6 months for
paclitaxel) and for up to 12
months in patients who are not
at high risk for bleeding. (Level
of Evidence: B)
4. A loading dose of clopidogrel,* generally
600 mg, should be administered before
or when PCI is performed. (Level of
Evidence: C) In patients undergoing PCI
within 12 to 24 hours of receiving
fibrinolytic therapy, a clopidogrel oral
loading dose of 300 mg may be
considered. (Level of Evidence: C)
1. A loading dose of thienopyridine is recommended for STEMI patients for
whom PCI is planned. Regimens should be 1 of the following:
a. At least 300 to 600 mg of clopidogrel† should be given as early as
possible before or at the time of primary or nonprimary PCI. (Level of
Evidence: C)
b. Prasugrel 60 mg should be given as soon as possible for primary PCI
(26,27). (Level of Evidence: B)
c. For STEMI patients undergoing nonprimary PCI, the following
regimens are recommended:
(i) If the patient has received fibrinolytic therapy and has been given
clopidogrel, clopidogrel should be continued as the thienopyridine
of choice (Level of Evidence: C);
(ii) If the patient has received fibrinolytic therapy without a
thienopyridine, a loading dose of 300 to 600 mg‡ of clopidogrel
should be given as the thienopyridine of choice (Level of
Evidence: C);
(iii) If the patient did not receive fibrinolytic therapy, either a loading
dose of 300 to 600 mg of clopidogrel should be given or, once
the coronary anatomy is known and PCI is planned, a loading
dose of 60 mg of prasugrel should be given promptly and no
later than 1 hour after the PCI (26,27). (Level of Evidence: B)
Modified recommendation
(changed text).
5. For all post-PCI stented patients receiving
a DES, clopidogrel 75 mg daily should be
given for at least 12 months if patients
are not at high risk of bleeding. For
post-PCI patients receiving a BMS,
clopidogrel should be given for a
minimum of 1 month and ideally up to
12 months (unless the patient is at
increased risk of bleeding; then it should
be given for a minimum of 2 weeks).
(Level of Evidence: B)
2. The duration of thienopyridine therapy should be as follows:
a. In patients receiving a stent (BMS or drug-eluting stent [DES]) during
PCI for ACS, clopidogrel 75 mg daily† (27–29) (Level of Evidence: B)
or prasugrel 10 mg daily§ (27) (Level of Evidence: B) should be given
for at least 12 months;
b. If the risk of morbidity because of bleeding outweighs the anticipated
benefit afforded by thienopyridine therapy, earlier discontinuation
should be considered. (Level of Evidence: C)
Modified recommendation
(pertains to STEMI and
unstable angina
UA/non-STEMI
NSTEMI based on
TRITON-TIMI 38).
07 STEMI Update, Section 9
In patients taking clopidogrel in
whom CABG is planned, the drug
should be withheld for at least 5
days and preferably for 7 days
unless the urgency for
revascularization outweighs the
risks of excess bleeding. (Level
of Evidence: B)
3. In patients taking a thienopyridine in whom CABG is planned and can
be delayed, it is recommended that the drug be discontinued to allow
for dissipation of the antiplatelet effect. (Level of Evidence: C) The
period of withdrawal should be at least 5 days in patients receiving
clopidogrel (2,30) (Level of Evidence: B) and at least 7 days in patients
receiving prasugrel† (27) (Level of Evidence: C), unless the need for
revascularization and/or the net benefit of the thienopyridine outweighs
the potential risks of excess bleeding (31). (Level of Evidence: C)
Modified recommendation
(added prasugrel).
Class IIa
04 STEMI Guidelines, Section
.4
2007 PCI Update, Table 14
1. If clopidogrel is given at the time of
procedure, supplementation with GP
IIb/IIIa receptor antagonists can be
beneficial. (Level of Evidence: B)
Deleted recommendation
2. For patients with an absolute
contraindication to aspirin, it is
reasonable to give a 300-mg to 600-mg
loading dose of clopidogrel, administered
at least 6 hours before PCI, and/or GP
IIb/IIIa antagonists, administered at the
time of PCI. (Level of Evidence: C)
Deleted recommendation
Class IIb
04 STEMI Guidelines, Section
.4
2007 PCI Update, Table 14
1. Continuation of clopidogrel therapy
beyond 1 year may be considered in
patients undergoing DES placement.
(Level of Evidence: C)
1. Continuation of clopidogrel or prasugrel§ beyond 15 months may be considered
in patients undergoing DES placement (27). (Level of Evidence: C)
Modified recommendation
(changed text).
(Continued)
ca
(P
la
fo
0.
in
to
m
an
P
pr
fo
w
th
R
cl
pr
of
cl
ra
ob
pa
1.
in
st
cr
gr
gr
pr
0.
2.
ve
P
pr
fe
(C
gr
3.
11
ne
m
fa
su
be
w
17
P
(9
ve
0.
w
th
A
(d
no
bl
Pa
(T
1.
an
Ta
ST
no
do
inh
do
wh
be
m
un
do
no
to
ble
fa
gr
an
(e inflamm
2213JACC Vol. 54, No. 23, 2009 Kushner et al.
December 1, 2009:2205–41 2009 Focused Updates: STEMI and PCI Guidelinesrdiovascular causes was also reduced in the prasugrel group
0.02). The difference in the primary end point was
rgely related to the difference in rates of nonfatal MI (7.3%
r prasugrel versus 9.5% for clopidogrel; HR 0.76; 95% CI
67 to 0.85; P0.001). There were no significant differences
the 2 treatment groups in the rates of stroke or of death due
cardiovascular causes not preceded by recurrent MI (at 15
onths, the nonfatal stroke rate was 1.0% for both prasugrel
d clopidogrel; HR for prasugrel1.02; CI 0.71 to 1.45;
0.93; the rate of deaths due to cardiovascular causes not
eceded by recurrent MI was 2.1% for prasugrel versus 2.4%
r clopidogrel; HR 0.89; CI 0.70 to 1.12; P0.31). There
ere significant reductions in the rates of ischemic events in
e prasugrel group compared with the clopidogrel group:
ates of MI were 7.4% for prasugrel versus 9.7% for
opidogrel (P0.001); urgent TVR rates were 2.5% for
asugrel versus 3.7% for clopidogrel (P0.001); and rates
stent thrombosis were 1.1% for prasugrel versus 2.4% for
opidogrel (HR 0.48; 95% CI 0.36 to 0.64; P0.001).
Prasugrel was associated with a significant increase in the
te of bleeding, notably, TIMI major hemorrhage, which was
served in 2.4% of patients taking prasugrel and in 1.8% of
tients taking clopidogrel (HR for prasugrel versus clopidogrel
32; 95% CI 1.03 to 1.68, P0.03), which represented an
crease in the relative rate of major bleeding of 32%. From the
andpoint of safety, prasugrel was associated with an in-
ease of 35 TIMI major and non–coronary artery bypass
aft bleeds (number needed to harm167) (27). Also,
eater rates of life-threatening bleeding were evident in the
asugrel group than in the clopidogrel group: 1.4% versus
9%, respectively (HR for prasugrel 1.52; 95% CI 1.08 to
ble 3. Continued
EMI Recommendations PCI Recommendations
Cl
1. In
at
as
*Available data for prasugrel use are for PCI for acute coronary syndrome (AC
t being updated in this guideline focused update.
†The optimum loading dose of clopidogrel has not been established. Randomiz
se of 300 mg orally followed by a daily oral dose of 75 mg (26,27). Higher oral
ibit platelet aggregation and achieve a higher absolute level of inhibition of pl
ses have not been rigorously established. The necessity for giving a loading
ich several hours are required to achieve desired levels of platelet inhibition. F
given for at least 12 months and for up to 15 months unless the risk of ble
‡Clopidogrel loading dose after fibrinolytic therapy: For patients given fibrin- an
g; for patients given a fibrin-specific fibrinolytic undergoing PCI after more t
dergoing PCI between 24 and 48 hours, 300 mg; for patients given a non–fi
§Patients weighing60 kg have an increased exposure to the active metaboli
se. Consideration should be given to lowering the maintenance dose to 5 mg
t been studied prospectively. For post-PCI patients receiving a stent (BMS or
15 months unless the risk of bleeding outweighs the anticipated net benefit a
eding or a history of transient ischemic attack or stroke. In patients 75 yea
tal and intracranial bleeding and uncertain benefit, except in high-risk situatio
eater and its use may be considered. Do not start prasugrel in patients likely t
y surgery. Additional risk factors for bleeding include body weight60 kg, prop
.g., warfarin, heparin, fibrinolytic therapy, or chronic use of nonsteroidal anti-13; P0.01), which included nonfatal bleeding (1.1% 0.rsus 0.9%; HR for prasugrel 1.25; 95% CI 0.87 to 1.81;
0.23) and fatal bleeding (0.4% versus 0.1%; HR for
asugrel 4.19; 95% CI 1.58 to 11.11; P0.002). In the
w patients who underwent coronary artery bypass graft
ABG), TIMI major bleeding through 15 months was also
eater with prasugrel than with clopidogrel (13.4% versus
2%, respectively; HR for prasugrel 4.73; 95% CI 1.90 to
.82; P0.001) (27). Despite the increase in bleeding, the
t clinical-benefit end point, which included all-cause
ortality, ischemic events, and major bleeding events,
vored prasugrel (27).
Prasugrel showed superior efficacy in major prespecified
bgroups in the overall ACS population. The benefit tended to
greater among the 3146 patients with diabetes (12.2% of
hom had the primary end point in the prasugrel group versus
.0% in the clopidogrel group; HR 0.70; 95% CI 0.58 to 0.85;
0.001) than among the 10 462 patients without diabetes
.2% of whom had the primary end point in the prasugrel group
rsus 10.6% in the clopidogrel group; HR 0.86; 95% CI 0.76 to
98; P0.02). The rate of definite or probable stent thrombosis
as significantly reduced in the prasugrel group compared with
e clopidogrel group, as noted (27).
A post hoc analysis suggested there were 3 subgroups of
CS patients who did not have a favorable net clinical benefit
efined as the rate of death due to any cause, nonfatal MI,
nfatal stroke, or non–CABG-related nonfatal TIMI major
eeding) from the use of prasugrel or who had net harm:
tients with a history of stroke or transient ischemic attack
IA) before enrollment had net harm from prasugrel (HR
54; 95% CI 1.02 to 2.32; P0.04), patients 75 years of age
d older had no net benefit from prasugrel (HR 0.99; 95% CI
Joint STEMI/PCI Focused Update Recommendations
Comments (All Modified
Recommendations Are for
Patients With ACS)
tients with a prior history of stroke and transient ischemic
hom primary PCI is planned, prasugrel is not recommended
dual-antiplatelet therapy regimen. (Level of Evidence: C)
New recommendation
not elective PCI. Recommendations for elective PCI with clopidogrel use are
establishing its efficacy and providing data on bleeding risks used a loading
doses such as 600 mg or more than 900 mg (36) of clopidogrel more rapidly
gregation, but the additive clinical efficacy and safety of higher oral loading
clopidogrel before PCI is driven by the pharmacokinetics of clopidogrel, for
PCI patients receiving a stent (BMS or DES), a daily maintenance dose should
utweighs the anticipated net benefit afforded by a thienopyridine.
fibrin-specific fibrinolytic drugs who are undergoing PCI within 24 hours, 300
hours, 300 to 600 mg; for patients given a non–fibrin-specific fibrinolytic
cific fibrinolytic undergoing PCI after 48 hours, 300 to 600 mg.
sugrel and an increased risk of bleeding on a 10-mg once-daily maintenance
ts who weigh 60 kg. The effectiveness and safety of the 5-mg dose have
daily maintenance dose should be given for at least 12 months and for up
y a thienopyridine. Do not use prasugrel in patients with active pathological
e, prasugrel is generally not recommended because of the increased risk of
nts with diabetes or a history of prior MI) in which its effect appears to be
o urgent CABG. When possible, discontinue prasugrel at least 7 days before
bleed, and concomitant use of medications that increase the risk of bleeding
atory drugs).2009
ass III
STEMI pa
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2009 Focused Updates: STEMI and PCI Guidelines December 1, 2009:2205–41an 60 kg had no net benefit from prasugrel (HR 1.03; 95%
I 0.69 to 1.53; P0.89). In both treatment groups, patients
ith at least 1 of these risk factors had higher rates of
eeding than those without them (27). A pharmacokinetic
alysis showed greater exposure to the active metabolite of
asugrel for patients who weighed less than 60 kg and who
ere 75 years old or older (38).
The US Food and Drug Administration (FDA) approved
asugrel in July 2009 and incorporated the aforementioned
bgroup findings into its labeling by citing a contraindica-
n against prasugrel use in patients with a history of TIA or
roke and active pathological bleeding. The FDA further
commends that consideration be given to lowering the
aintenance dose of prasugrel to 5 mg in patients who weigh
ss than 60 kg, with a note that the effectiveness and safety
the 5-mg dose have not been studied prospectively to date.
he FDA labeling information includes a general warning
ainst the use of prasugrel in patients older than 75 years of
e because of concerns of an increased risk of fatal and
tracranial bleeding and uncertain benefit, except in high-
sk situations (patients with diabetes or a history of prior
I), in which case its effect appears to be greater and its use
ay be considered (37).
In focusing specifically on patients with STEMI, the
imary composite end point of cardiovascular death, nonfa-
l MI, or nonfatal stroke was significantly reduced in patients
signed to prasugrel at 30 days compared with patients who
ceived clopidogrel (6.5% versus 9.5%; HR 0.68; 95% CI
54 to 0.87; P0.0017), and this trend persisted to 15
onths (HR 0.79; 95% CI 0.65 to 0.97; P0.0221) (13).
rthermore, in the STEMI group, the key secondary end
int of cardiovascular death, MI, or urgent TVR was
gnificantly reduced with prasugrel at 30 days (P0.0205)
d 15 months (P0.0250) (13). At 30 days and 15 months,
e individual end points of cardiovascular death and MI, as
ell as stent thrombosis, were reduced with prasugrel (13).
The interaction testing for efficacy and safety showed no
gnificant difference in bleeding risk regardless of the type
ACS (e.g., UA/NSTEMI versus STEMI). Thus, the STEMI
sults for efficacy and safety are consistent with the main
sults of the trial. In a post hoc analysis of patients with
terior MI, event rates at 15 months for the primary end
int were lower with prasugrel (9.8% for prasugrel versus
.3% for clopidogrel; HR 0.57; 95% CI 0.42 to 0.78;
0.0003). In patients with nonanterior MI, treatment effects
d not differ for the primary end point (10.1% for prasugrel
rsus 9.9% for clopidogrel; HR 1.02; 95% CI 0.78 to 1.34;
0.8749). The test for heterogeneity of the effect of
asugrel was significant (P0.0053), which suggests that
e benefit might vary by the location of the MI. Data were
nsistent in both the primary and secondary PCI subgroups
3).
The writing group weighed the current data regarding the
e of thienopyridine therapy in patients who remain hospi-
lized after STEMI and are candidates for CABG and
tained the 2007 focused update recommendation of empiric
scontinuation of clopidogrel therapy for at least 5 days and
least 7 days in patients receiving prasugrel before plannedABG (2,27,30). grPlatelet function testing to determine the degree of platelet
hibition (39) may be used, and if platelet function has normal-
ed, CABG may be performed at an earlier time. Additionally,
her strategies of platelet inhibition (GP IIb/IIIa receptor antag-
ists) may be used if recurrent ischemia is a concern during the
aiting period for CABG. Ultimately, the patient’s clinical
atus will determine the risk-to-benefit ratio of CABG com-
red with awaiting restoration of platelet function.
The results of TRITON-TIMI 38 influenced dosing recom-
endations for loading and chronic thienopyridine therapy
ith prasugrel. Sixty milligrams of prasugrel is now recom-
ended as a loading dose for primary PCI in STEMI. For
condary PCI in those patients who have recurrent ischemia
other reasons for planned intervention during their course
treatment, 60 mg of prasugrel may be given after the
ronary anatomy has been identified (to avoid dosing those
tients who require CABG) either before, during, or within
hour of PCI (27). Furthermore, 10 mg of prasugrel may be
ed in addition to ASA for chronic dual-antiplatelet therapy
7).
Determination of patient groups that should be considered
r continuation of dual-antiplatelet treatment beyond 12
onths is based on patient-level factors (e.g., age, history of
eeding) and lesion characteristics (e.g., bifurcation, small-
ameter vessel) (28).
In previous studies of patients with prior stroke or TIA, use
dual-antiplatelet therapy has been associated with an
creased risk of adverse outcomes, notably intracranial
eeding, compared with single-antiplatelet therapy. In the
ATCH (Management of Atherothrombosis With Clopi-
grel in High-Risk Patients With TIA or Stroke) trial (40) in
hich patients with prior stroke or TIA and additional risk
ctors (n7599) were allocated to clopidogrel 75 mg or
mbination therapy with clopidogrel 75 mg plus ASA 75 mg
r day, there was no significant benefit of combination
erapy compared with clopidogrel alone in reducing the
imary outcome of the composite of ischemic stroke, MI,
scular death, or rehospitalization due to ischemic events, or
y of the secondary outcomes. The risk of major hemorrhage
as significantly increased in the combination-therapy group
mpared with those given clopidogrel alone, with a 1.3%
solute increase in life-threatening bleeding. Although clo-
dogrel plus ASA is recommended over ASA alone for
tients with ACS (41–43), the results of MATCH do not
ggest a similar risk-benefit ratio for stroke and TIA
rvivors. The AHA/American Stroke Association’s Guide-
es for Prevention of Stroke in Patients With Ischemic
roke or Transient Ischemic Stroke contain a Class III
commendation for the use of ASA in combination with
opidogrel in patients with prior stroke or TIA (44). On the
her hand, a post hoc analysis from the CHARISMA
lopidogrel for High Atherothrombotic Risk and Ischemic
abilization, Management, and Avoidance) trial, which in-
uded 9478 patients, suggested that patients with docu-
ented prior MI, ischemic stroke, or symptomatic peripheral
tery disease derive benefit from dual-antiplatelet therapy
ith clopidogrel plus ASA (45). Although MATCH and
HARISMA did not involve STEMI patients, the writing
oup recommended weighing the benefits and risks of
pr
hi
to
an
w
pa
pr
3.
A
sh
ta
do
be
va
w
2C
fa
cl
th
re
lo
is
ev
(5
an
ev
ha
cl
m
ua
ra
ad
fu
ou
ta
fo
ho
m
th
ha
ha
do
th
C
T
w
w
ST
da
20
cl
ac
th
a
ev
op
el
Fo
su
of
re
PC
m
tr
30
re
de
th
cl
3.
T
ri
de
pr
M
w
co
A
w
Fu
th
bu
se
no
co
th
ri
at
an
w
ch
3.
T
Pr
la
tin
(5
cl
te
pr
th
(B
re
in
in
no
cl
*P
pr
2215JACC Vol. 54, No. 23, 2009 Kushner et al.
December 1, 2009:2205–41 2009 Focused Updates: STEMI and PCI Guidelinesescribing clopidogrel and ASA in patients with a recent
story of TIA or stroke. Given prasugrel’s greater tendency
cause intensive inhibition of platelet aggregation in general
d the findings of increased levels of bleeding compared
ith clopidogrel in this population, the use of prasugrel as
rt of a dual-antiplatelet therapy regimen in patients with
ior stroke or TIA is contraindicated (37).
1.1. Additional Thienopyridine Information
lthough clopidogrel in combination with ASA has been
own to reduce recurrent coronary events in the posthospi-
lized ACS population (32,43,46), the response to clopi-
grel varies among patients, and clopidogrel resistance has
en observed (43). Information is accumulating about the
riations in the antiplatelet effect of clopidogrel in patients
ith loss-of-function alleles in the gene encoding CYP450
19 (32,46–50). These patients form a subgroup in which
ilure of clopidogrel effectiveness has been linked to adverse
inical outcomes (30,47–51). In TRITON-TIMI 38 and 3 of
e cohort studies (47,49,52), patients who were carriers of a
duced-function CYP450 2C19 allele had significantly
wer levels of the active metabolite of clopidogrel, dimin-
hed platelet inhibition, and increased rates of cardiovascular
ents (e.g., death, MI, stroke), including stent thrombosis
3), compared with the extensive metabolizers (54). In
other cohort study with 2208 patients (50), the increased
ent rate was observed only in poor metabolizers. (Prasugrel
s a higher level of inhibition of platelet aggregation than
opidogrel and a more rapid onset of action [55]. Its
etabolism is not affected by the 2C19 allele variant [56].)
Accordingly, the effective clopidogrel dose for an individ-
l undergoing PCI for STEMI may not be known. A large
ndomized trial (57) is attempting to determine whether
justment of clopidogrel therapy on the basis of platelet
nction testing with a point-of-care assay safely improves
tcomes after PCI with DES. As noted in the drug dosing
ble (Appendix 4), the current recommended loading dose
r clopidogrel is uncertain. In addition, a period of several
urs is required to metabolize clopidogrel to its active
etabolite, which leaves a window of time during which
ere is a reduced level of effectiveness even in responders.
With regard to clopidogrel loading for PCI after a patient
s received fibrinolytic therapy, there are no studies that
ve formally tested a 600-mg (or higher) clopidogrel loading
se administered with fibrinolytic treatment. The only study
at tested any clopidogrel dose with a fibrinolytic was the
LARITY-TIMI 28 (Clopidogrel as Adjunctive Reperfusion
herapy–Thrombolysis in Myocardial Infarction 28) study,
hich randomized 3491 patients 75 years of age and younger
ho were receiving fibrinolytic therapy within 12 hours of
EMI to clopidogrel (300-mg oral loading dose; 75-mg oral
ily maintenance dose) or placebo (58). As described in the
07 STEMI focused update (4), patients who received
opidogrel had a reduced rate of an occluded infarct artery,
complished by preventing infarct-related reocclusion rather
an by facilitating early reperfusion.
When considering a loading dose of clopidogrel for PCI after
patient has received a fibrinolytic agent, the available level of
idence is limited (Level of Evidence: C), and consensus thinion suggests it is dependent on how many hours have
apsed since fibrinolytic therapy was administered before PCI.
r patients who have received any fibrinolytic agent and
bsequently proceed to PCI within 24 hours, a dose of 300 mg
clopidogrel as a loading dose is suggested. If the patient
ceived a fibrin-specific fibrinolytic agent and then proceeds to
I after 24 hours has elapsed, a loading dose of 300 to 600 mg
ay be considered. If at least 48 hours has elapsed after
eatment with a non–fibrin-specific fibrinolytic agent, a dose of
0 to 600 mg may be considered.
Prasugrel has not been studied in patients who have
ceived fibrinolytic therapy. Thus, for STEMI patients un-
rgoing nonprimary PCI who received prior fibrinolytic
erapy without a thienopyridine, only a loading dose with
opidogrel should be given as the thienopyridine of choice.
1.2. Choice of Thienopyridine for PCI in STEMI
he guidelines do not endorse explicitly one of the thienopy-
dines over the other. There were several reasons for this
cision. Although the composite efficacy end point favored
asugrel, driven predominantly by a difference in nonfatal
Is, with deaths and nonfatal strokes being similar, bleeding
as increased in the prasugrel group (27). In addition, the
mparison of the 2 drugs is based on a single large trial.
lso, the loading dose of clopidogrel in TRITON-TIMI 38
as lower than is currently recommended in these guidelines.
rthermore, there are some emerging studies that suggest
ere may be some patients who are resistant to clopidogrel,
t there is little information about the use of strategies to
lect patients who might do better with prasugrel. There is
t yet experience with the use of prasugrel in routine
mmunity practice. As a result, the writing group believes
at there is some uncertainty regarding the net benefit and
sks of 1 drug over another for a given patient. Consider-
ions of efficacy in the prevention of thrombosis and risk of
adverse effect related to bleeding, as well as experience
ith a given medication, may best guide decisions about the
oice of thienopyridine for individual patients.
2. Proton Pump Inhibitors and Dual-Antiplatelet
herapy for ACS
oton pump inhibitors (PPIs) are often prescribed prophy-
ctically when clopidogrel is started, to prevent gastrointes-
al complications such as ulceration and related bleeding
9) due to dual-antiplatelet therapy, in particular ASA and
opidogrel (32). Coupled with concern about the gastroin-
stinal precautions, there has been increased emphasis on the
evention of premature discontinuation of dual-antiplatelet
erapy, particularly in patients who have received a stent
MS or DES), for whom 12 months of antiplatelet therapy is
commended (28). PPI medications* have been found to
terfere with the metabolism of clopidogrel (34).
Although there are studies that show a pharmacodynamic
teraction on ex vivo platelet function testing, to date there are
convincing randomized clinical trial data for an important
inical drug–drug interaction. Retrospective claims-based re-
PIs include omeprazole, lansoprazole, pantoprazole, rabeprazole, and esome-
azole (which are all available by prescription). Omeprazole is also sold over
e counter for frequent heartburn (66).
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nfounded by different baseline characteristics and lack of
mpliance data. There have been retrospective reports of
verse cardiovascular outcomes (e.g., readmission for ACS)
hen the antiplatelet regimen of clopidogrel and ASA is
companied by PPIs, assessed as a group, compared with the
e of this regimen without a PPI (32–34,60). In a retrospective
hort study from the Veterans Affairs’ medical records and
armacy database, concomitant clopidogrel and PPI therapy
ith omeprazole, rabeprazole, lansoprazole, or pantoprazole) at
y time point during follow-up of 8205 patients discharged for
CS was associated with an increased risk of death or rehospi-
lization for ACS (32). Other post hoc study analyses (50,61)
d a retrospective data analysis from the NHLBI Dynamic
egistry (62) in which PPIs were assessed as a class in
mbination with a clopidogrel and an ASA regimen have not
und an effect of PPI therapy on the clinical effect of clopi-
grel in ACS patients, after ACS, or in a general post-PCI
pulation, respectively (50,61,62).
Some studies have suggested that adverse cardiovascular
tcomes with the combination of clopidogrel and a PPI are
plained by the individual PPI, in particular the use of a PPI
at inhibits CYP450 2C19, which includes omeprazole,
nsoprazole, and rabeprazole. The PPI omeprazole notably
s been reported to significantly decrease the inhibitory
fect of clopidogrel on platelet aggregation (63,64). One
udy reported that the PPI pantoprazole was not associated
ith recurrent MI among patients receiving clopidogrel,
ssibly because of its lack of inhibition of CYP450 2C19 (33).
Other studies have examined the thienopyridine agent
escribed with the PPI. One open-label drug study evaluated
e effects of the PPI lansoprazole on the pharmacokinetics
d pharmacodynamics of prasugrel and clopidogrel in
althy subjects given single doses of prasugrel (60 mg) and
opidogrel (300 mg) with and without concurrent lansopra-
le 30 mg per day. The data suggest that inhibition of
atelet aggregation was reduced in patients who took the
mbination of clopidogrel and lansoprazole, whereas it was
affected after a prasugrel dose (56).
Another study (35) assessed the association of PPIs with
e pharmacodynamics and clinical efficacy of clopidogrel
d prasugrel, based on populations from 2 randomized trials,
e PRINCIPLE (Prasugrel In Comparison to Clopidogrel for
hibition of Platelet Activation and Aggregation) TIMI-44
ial (65) and the TRITON-TIMI 38 trial (27). The findings
dicated that first, PPI treatment attenuated the pharmaco-
namic effects of clopidpgrel and, to a lesser extent, those of
asugrel. Secondly, PPI treatment did not affect the clinical
tcome of patients given clopidogrel or prasugrel. This
nding was true for all PPIs that were studied, including
eprazole and pantoprazole.
The FDA communication concerning an ongoing safety
view of clopidogrel bisulfate (66) advises that healthcare
oviders avoid the use of clopidogrel in patients with
paired CYP2C19 function due to known genetic varia-
on or due to drugs that inhibit CYP2C19 activity. The
DA notes there is no evidence that other drugs that reduce
omach acid, such as H2 blockers or antacids, interfere
ith the antiplatelet activity of clopidogrel. diFurther research with thienopyridines and PPI combina-
ns, particularly drugs that are not dependent on CYP450
19, is needed. Consideration may be given to the use of H2
tagonists as an alternative to PPIs in the setting of dual-
tiplatelet therapy, although they cannot be relied on to
otect as well as PPIs, and there are few data about their use
ith ASA (59). The FAMOUS (Famotidine for the Preven-
n of Peptic Ulcers in Users of Low-Dose Aspirin) trial, a
ase II, double-blind, randomized, placebo-controlled trial,
und that among patients with a history of coronary heart
sease, diabetes mellitus, or cerebrovascular disease who
ere taking low-dose ASA, 12 weeks of famotidine 20 mg
ice daily (n204) compared with placebo twice daily
200) was beneficial in reducing the incidence of peptic
cer or esophagitis during follow-up endoscopy at 12 weeks.
he rate of occurrence of a gastric ulcer at endoscopy at 12
eeks was 3.4% in the famotidine group versus 15% in the
acebo group (P0.0002), duodenal ulcer occurred in 0.5%
rsus 8.5% (P0.0045), and erosive esophagitis was seen in
4% versus 19% (P0.0001), respectively. Of note, in the
motidine group, clopidogrel use was 19% and dipyridamole
e was 6% (67). The writing committee concluded that
ditional data, notably randomized controlled clinical trial
ta that have been peer reviewed and published, are needed
fore an official recommendation can be made about the use
dual antiplatelet therapy with PPIs in the setting of ACS.
. Recommendations for the Use of
arenteral Anticoagulants
ee Table 4 and Appendix 4.)
1. Parenteral Anticoagulants
renteral anticoagulants include intravenous UFH, bivaliru-
n, enoxaparin, and fondaparinux. Bivalirudin was briefly
ted in the 2007 STEMI focused update. The HORIZONS-
MI trial, which was reported subsequently, was a prospec-
e, open-label, randomized, multicenter, international trial
at included 3602 patients with STEMI undergoing primary
I. Patients were randomized to treatment with UFH plus a
P IIb/IIIa receptor antagonist or to bivalirudin alone (with
ovisional abciximab or double-bolus eptifibatide). The
imary efficacy end point was a composite of net adverse
inical events, including major bleeding plus MACE, a
mposite of cardiovascular death, reinfarction, TVR for
chemia, and stroke within 30 days. Bivalirudin alone
sulted in a lower incidence of net adverse clinical events at
days (9.2% versus 12.1%; RR 0.76; 95% CI 0.63 to 0.92;
0.005; NNT34) and at 1 year (15.7% versus 18.3%, HR
84; 95% CI 0.71 to 0.98; P0.3) (9). The difference was
iven by a significant decrease in major bleeding complica-
ns with bivalirudin at 30 days (4.9% versus 8.3%,
0.001; number needed to harm33) and 1 year (5.8%
rsus 9.2%, P0.001). There was a statistically significant
increase in stent thrombosis (n17) within the first 24
urs with bivalirudin but no subsequent difference (1.3%
rsus 0.3%, P0.001). More deaths at 30 days occurred
ter major bleeding (n26) than after reinfarction (n10) or
finite stent thrombosis (n5) (9). Treatment with bivaliru-
n resulted in significantly lower 30-day rates of death due to
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95; P0.03) and death due to all causes (2.1% versus 3.1%;
R 0.66; 95% CI 0.44 to 1.00; P0.047 compared with UFH
us GP IIb/IIIa inhibitors). At 1 year, MACE rates were
entical, but there was a decrease in all-cause mortality with
valirudin (3.4% versus 4.8%, P0.03) (68).
Concerns about the trial include its open-label design and
e administration of UFH before randomization in 66% of
tients in the bivalirudin arm and 76% of patients in the
FH plus GP IIb/IIIa receptor antagonist arm. Only 615
tients received bivalirudin monotherapy, and only 60% of
tients in the trial received a 600-mg clopidogrel loading
se. Major bleeding as defined in the publication included
matomas of 5 cm, intracranial hemorrhage, and bleeding
at required surgery. Additionally, the study put forth a
mposite primary end point that combined efficacy and
fety. Although there were no statistically significant inter-
tions at 30 days between the treatment assignment and
eprocedural UFH use or clopidogrel loading dose with
spect to MACE or major bleeding, the occurrence of an
crease in early stent thrombosis with bivalirudin and the
cess bleeding with UFH and GP IIb/IIIa inhibitors may be
lated to the degree of platelet inhibition and antithrombin
ble 4. Recommendations for the Use of Parenteral Anticoagula
EMI Recommendations PCI Recommendations
07 STEMI Update, Section 8 2007 PCI Guideline Update, Table 13
C
For patients undergoing PCI after having
received an anticoagulant regimen, the
following dosing recommendations should
be followed:
a. For prior treatment with UFH,
administer additional boluses of UFH
as needed to support the procedure,
taking into account whether GP IIb/IIIa
receptor antagonists have been
administered. (Level of Evidence: C)
Bivalirudin may also be used in
patients treated previously with UFH.
(Level of Evidence: C)
b. For prior treatment with enoxaparin, if
the last subcutaneous dose was
administered within the prior 8 hours,
no additional enoxaparin should be
given; if the last subcutaneous dose
was administered at least 8 to 12
hours earlier, an intravenous dose of
0.3 mg per kg of enoxaparin should
be given. (Level of Evidence: B)
c. For prior treatment with fondaparinux,
administer additional intravenous
treatment with an anticoagulant
possessing anti-IIa activity taking into
account whether GP IIb/IIIa receptor
antagonists have been administered.
(Level of Evidence: C)
1. For patients undergoing PCI after having
an anticoagulant regimen, the following
recommendations should be followed:
a. For prior treatment with UFH, administe
additional boluses of UFH as needed to
the procedure, taking into account whe
IIb/IIIa receptor antagonists have been
administered. (Level of Evidence: C) Biv
may also be used in patients treated pr
with UFH. (Level of Evidence: C)
b. For prior treatment with enoxaparin, if t
subcutaneous dose was administered a
to 12 hours earlier, an IV (intravenous)
0.3 mg/kg of enoxaparin should be give
last subcutaneous dose was administer
the prior 8 hours, no additional enoxapa
should be given. (Level of Evidence: B)
c. For prior treatment with fondaparinux, a
additional intravenous treatment with an
anticoagulant possessing anti-IIa activity
into account whether GP IIb/IIIa recepto
antagonists have been administered. (Le
Evidence: C)
Cltivity associated with these treatment doses. PA preliminary report suggested that the use of bivalirudin
one (P0.005) and a lower loading dose of clopidogrel
00 versus 600 mg; P0.01) were independent predictors of
ute and subacute stent thrombosis rates, respectively (69).
obability values for secondary end points may not have
en adjusted for multiple looks.
Therefore, the writing group now considers bivalirudin
eful for primary PCI in STEMI whether or not the patient
ceived pretreatment with UFH. The risk of acute stent
rombosis associated with bivalirudin appeared to be miti-
ted by the prior use of UFH and the risk of subacute stent
rombosis by the use of a 600-mg loading dose of clopi-
grel. These data should be confirmed by prospective
udies.
. Recommendations for Triage and
ansfer for PCI
ee Table 5 and Appendix 5.)
1. Triage and Transfer for PCI
1.1. STEMI Patients Who Are Candidates for Reperfusion
he 2007 STEMI Focused Update describes several strate-
es for reperfusion, among them facilitated PCI and rescue
2009 Joint STEMI/PCI Focused Update
Recommendations Comments
1. For patients proceeding to primary
PCI who have been treated with
ASA and a thienopyridine,
recommended supportive
anticoagulant regimens include the
following:
a. For prior treatment with UFH,
additional boluses of UFH should
be administered as needed to
maintain therapeutic activated
clotting time levels, taking into
account whether GP IIb/IIIa
receptor antagonists have been
administered. (Level of
Evidence: C)
b. Bivalirudin is useful as a
supportive measure for primary
PCI with or without prior treatment
with UFH (9). (Level of
Evidence: B)
Modified recommendation. (Bivalirudin
was added as an acceptable
anticoagulant for primary PCI; text
about UFH was modified to
mention activated clotting time
levels. Information on enoxaparin
and fondaparinux was not
imported because
recommendations concerning
these drugs were unchanged.)
1. In STEMI patients undergoing PCI
who are at high risk of bleeding,
bivalirudin anticoagulation is
reasonable (9). (Level of Evidence: B)
New recommendationnts
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2009 Focused Updates: STEMI and PCI Guidelines December 1, 2009:2205–41tions in this update so that the contemporary therapeutic
oices that lead to reperfusion as part of the treatment of
tients presenting with STEMI can be described without
ese potentially misleading labels.
A brief review of facilitated PCI, however, is needed. This
rategy involves full- or half-dose fibrinolytic therapy with
without a GP IIb/IIIa receptor antagonist, followed by
mediate PCI. Two studies addressed this issue: ASSENT-4
I (Assessment of the Safety and Efficacy of a New
reatment Strategy With Percutaneous Coronary Interven-
n) (70), which was described in detail in the 2007 PCI and
EMI focused updates, and FINESSE (71), which was a
ble 5. Recommendations for Triage and Transfer for PCI
04/2005/2007 Recommendations 2009 Joint STEMI/P
C
1. Each community
standards at leas
national initiative
● ongoing multid
medical servic
centers, and P
evaluate outco
● a process for p
● destination pro
● transfer protoc
who are prima
drugs, and/or a
Cla
1. It is reasonable f
therapy as prima
to be transferred
PCI can be perfo
strategy. Conside
antithrombotic (a
during patient tra
(Level of Evidenc
Cla
rom 2007 STEMI Update, Section 5)
Facilitated PCI using regimens other than full-dose
fibrinolytic therapy might be considered as a
reperfusion strategy when all of the following are
present: a. Patients are at high risk, b. PCI is not
immediately available within 90 minutes, and c.
Bleeding risk is low (younger age, absence of
poorly controlled hypertension, normal body
weight). (Level of Evidence: C)
1. Patients who are
primary reperfusi
considered for tr
where PCI can b
pharmacoinvasive
initiating a prepa
regimen before a
laboratory. (Leve
rom 2007 STEMI Update, Section 6)
A strategy of coronary angiography with intent to
perform PCI in the absence of 1 or more of the
above Class I or IIa indications might be
reasonable in moderate- and high-risk patients,
but its benefits and risks are not well established.
The benefits of rescue PCI are greater the earlier
it is initiated after the onset of ischemic
discomfort. (Level of Evidence: C)
*High risk was defined in the CARESS-in-AMI (15) study as STEMI patients with
ck, previous MI, Killip class2, or left ventricular ejection fraction35% for
e patient as being at high risk). It was defined in TRANSFER-AMI (14) as 2
erior leads with at least 1 of the following: systolic blood pressure 100 mm
the anterior leads, or 1 mm of ST elevation in right-sided lead V4 indicativndomized, double-blind clinical trial of 2452 patients ran- admized within 6 hours of symptom onset to receive reduced-
se reteplase plus abciximab followed by PCI (combination-
cilitated PCI), abciximab alone followed by PCI (abciximab-
cilitated PCI), or placebo (primary PCI).
ASSENT-4 patients treated with fibrinolytic therapy
fore PCI had increased rates of adverse outcomes,
cluding in-hospital death (6% versus 3%). The investi-
tors theorized that suboptimal antithrombotic therapy
.e., the lack of a heparin infusion after bolus administra-
on, no upfront loading dose of clopidogrel, and prohibi-
on of IIb/IIIa use except for bailout) and a short time
om fibrinolytic therapy to PCI contributed in part to the
ed Update Recommendations Comments
develop a STEMI system of care that follows
ngent as those developed for the AHA’s
n: Lifeline, to include the following:
ry team meetings that include emergency
PCI-capable hospitals/STEMI referral
le hospitals/STEMI receiving centers to
quality improvement data;
tal identification and activation;
r STEMI receiving centers;
atients who arrive at STEMI referral centers
andidates, are ineligible for fibrinolytic
rdiogenic shock. (Level of Evidence: C)
New recommendation
risk* patients who receive fibrinolytic
fusion therapy at a non–PCI-capable facility
as possible to a PCI-capable facility where
ther when needed or as a pharmacoinvasive
hould be given to initiating a preparatory
lant plus antiplatelet) regimen before and
the catheterization laboratory (14,15).
New recommendation
(see Appendix 5)
igh risk who receive fibrinolytic therapy as
py at a non–PCI-capable facility may be
s soon as possible to a PCI-capable facility
med either when needed or as a
y. Consideration should be given to
ntithrombotic (anticoagulant plus antiplatelet)
g patient transfer to the catheterization
ence: C)
Modified
recommendation
(changed text).
Deleted recommendation
(covered by new
recommendations,
above)
-risk feature (extensive ST-segment elevation, new-onset left bundle-branch
Is; anterior MI alone with2 mm of ST elevation in2 leads also qualified
T-segment elevation in 2 anterior leads or ST elevation of at least 1 mm in
art rate 100 bpm, Killip class II to III, 2 mm of ST-segment depression
t ventricular involvement.CI Focus
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ab and reteplase nor PCI preceded by abciximab alone was
perior to abciximab used at the time of PCI among patients
esenting within 4 hours of medical contact. Neither the
imary end point (a composite of death due to all causes,
ntricular function more than 48 hours after randomization,
rdiogenic shock, and congestive heart failure during the
rst 90 days after randomization) nor mortality was signifi-
ntly different among the groups. Although the study was
rminated early because of recruitment challenges, there was
ss than a 2% chance that the primary treatment group
fference would be significant if the trial had been allowed
continue to its planned completion.
The indications for rescue PCI have been defined by a
mbination of clinical and electrocardiographic clues that an
farct artery has not reperfused. These are relief of pain and
solution of ST-segment elevation. Although complete relief
pain and complete resolution of ST elevation are reason-
ly predictive of reperfusion after fibrinolytic therapy, this is
t a common occurrence. In the 2007 STEMI Focused
pdate, the writing committee held that at 90 minutes after
itiation of fibrinolytic therapy, if there was less than 50%
-segment resolution in the lead that showed the greatest
gree of ST elevation at presentation, then fibrinolytic
erapy had likely failed to reperfuse the patient (4). If the
dgment was made that fibrinolytic therapy had not resulted
reperfusion after 90 minutes, then PCI performed at that
e was labeled rescue PCI.
The 2007 STEMI Focused Update (4) recommended res-
e PCI in the following cases: Fibrinolytic-treated STEMI
tients meeting high-risk criteria (i.e., cardiogenic shock
ess than 75 years of age, Class I; 75 years of age or older,
lass IIa]); hemodynamic or electrical instability; persistent
chemic symptoms; and for certain moderate- and high-risk
tients who did not strictly meet the above criteria (Class
b). These recommendations were based on results of the
EACT (Rescue Angioplasty Versus Conservative Treat-
ent of Repeat Thrombolysis) trial (74) which showed a
ear benefit of rescue PCI (over repeated doses of fibrino-
tics or medical management) in moderate- to high-risk
tients with failed reperfusion, as well as a meta-analysis of
rescue PCI trials (including REACT) (73–76). The 2007
cused update acknowledged that the expected benefits of
scue PCI are greater the earlier it is initiated after the onset
ischemic symptoms.
Two new trials have helped inform this update: The
ARESS-in-AMI trial and the TRANSFER-AMI trial.
ARESS-in-AMI (15) studied 600 STEMI patients 75 years
age or younger with at least 1 high-risk feature (extensive
-segment elevation, new-onset left bundle-branch block,
evious MI, Killip class greater than 2, or left ventricular
ection fraction 35% or less) who were treated initially at
n-PCI hospitals with half-dose reteplase, abciximab, hep-
in, and ASA within 12 hours of symptom onset (3). All
tients were randomized to immediate transfer for PCI or to
andard treatment with transfer for rescue PCI if needed. PCI
as performed in 85.6% of patients in the immediate PCI
oup, and rescue PCI was performed in 30.3% of the
andard treatment/transfer for rescue PCI group. There was a anorter median time from fibrinolytic therapy to transfer to a
I-capable center in the immediate versus the rescue PCI
oup (110 versus 180 minutes, P0.0001). Antiplatelet
erapy with ASA and clopidogrel was used less frequently in
e standard care/rescue arm than in the early intervention
oup. The primary outcome (composite of all-cause mortal-
, reinfarction, and refractory myocardial ischemia within
days of randomization) occurred significantly less often
.4% versus 10.7%, P0.004) in the immediate PCI group
an in the standard care/rescue PCI group (NNT17). There
ere no significant differences in the rates of major bleeding
30 days (3.4% versus 2.3%, P0.47) or stroke (0.7%
rsus 1.3%, P0.50) between groups. These results suggest
at high-risk STEMI patients treated at non-PCI hospitals
ith a preparatory pharmacological strategy of half-dose
brinolytic therapy, abciximab, heparin, and ASA have
proved outcomes when transferred immediately to a PCI
cility rather than when medical therapy is continued with
ansfer for rescue PCI only if there is evidence of failed
perfusion.
The TRANSFER-AMI study (14) further tested the phar-
acoinvasive strategy concept in high-risk STEMI patients.
ccordingly, 1059 patients who presented to a non–PCI-
pable hospital within 12 hours of symptom onset of STEMI
ho had at least 1 high-risk feature (greater than or equal to
mm of ST-segment elevation in 2 anterior leads, systolic
ood pressure less than 100 mm Hg, heart rate higher than
0 bpm, Killip class II to III, 2 mm or more of ST-segment
pression in the anterior leads, or 1 mm or more of ST
evation in right-sided lead V4 indicative of right ventricular
volvement for inferior MIs; anterior MI alone with 2 mm or
ore of ST-segment elevation in 2 or more leads also
alified) and who were treated with fibrinolytic therapy
ere randomized to a pharmacoinvasive strategy (immediate
ansfer for PCI within 6 hours of fibrinolytic therapy) or to
andard treatment after fibrinolytic therapy, which included
scue PCI as required for ongoing chest pain and less than
% resolution of ST elevation at 60 to 90 minutes or
modynamic instability. Standard-treatment patients who
d not require rescue PCI remained at the initial hospital for
least 24 hours, and coronary angiography within the first 2
eeks was encouraged.
All patients received standard-dose tenecteplase, ASA, and
ther UFH or enoxaparin. Clopidogrel loading (300 mg for
tients 75 years of age or younger and 75 mg for those older
an 75 years of age) was strongly encouraged in all study
tients. GP IIb/IIIa receptor antagonists were administered
the PCI-capable hospitals according to standard practice at
e institution. The primary end point of the trial was the
-day composite of the first occurrence of death, reinfarc-
n, recurrent ischemia, new or worsening heart failure, and
rdiogenic shock.
The median time to administration of tenecteplase from
set of symptoms was approximately 2 hours in both groups,
hereas the median time from tenecteplase administration to
theterization was 2.8 hours in the pharmacoinvasive group
d 32.5 hours in the standard-treatment group. Coronary
giography was performed in 98.5% versus 88.7% and PCI
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andard-treatment groups, respectively.
The primary end point of the trial occurred in 11.0% of the
armacoinvasive group compared with 17.2% of the
andard-treatment group (RR 0.64; 95% CI 0.47 to 0.84;
0.004). Importantly, the incidence of TIMI major and
inor bleeding and GUSTO (Global Use of Strategies to
pen Occluded Coronary Arteries) (77) moderate and severe
eeding was not different between groups, although there
as a higher incidence of GUSTO mild bleeding in the
armacoinvasive group (13.0% compared with 9.0% in the
andard-treatment group, P0.036). The authors concluded
at after treatment with fibrinolytic therapy in STEMI
tients presenting to hospitals without PCI capability, trans-
r to a PCI center to undergo coronary angiography and PCI
ould be initiated immediately without waiting to determine
hether reperfusion has occurred. These results lend further
pport to the routine, early transfer of high-risk, fibrinolytic-
eated patients to a PCI center for early PCI supported by
ntemporary antiplatelet and antithrombotic therapy.
On the basis of this evidence, a pathway has been sug-
sted for the care of STEMI patients that has been divided
to those patients presenting to a PCI-capable facility and
ose presenting to a non–PCI-capable facility (Appendix 5).
hose seen at a PCI-capable facility should be moved
peditiously to the catheterization laboratory, with appropri-
e antithrombotic therapy for catheterization and PCI if
propriate. There has been discussion about whether the
commended door-to-balloon time (or first medical contact–
-balloon time) should be greater than 90 minutes, with the
cognition that in certain patients, the mortality advantage of
imary PCI compared with fibrinolytic therapy is maintained
ith more prolonged door-to-balloon times (78). However,
e writing groups continue to believe that the focus should
on developing systems of care to increase the number of
tients with timely access to primary PCI rather than
tending the acceptable window for door-to-balloon time
9). Moreover, in a study of 43 801 patients with STEMI
dergoing primary PCI within the National Cardiovascular
ata Registry, any delay in time to reperfusion after arrival at
e hospital was associated with a higher adjusted risk of
-hospital mortality in a continuous, nonlinear fashion (30
inutes3.0%, 60 minutes3.5%, 90 minutes4.3%, 120
inutes5.6%, 150 minutes7.0%, and 180 minutes8.4%;
0.001) (80). Rather than accepting a 90-minute door-to-
lloon benchmark for primary PCI, these data suggest an
-soon-as-possible standard.
Those patients presenting to a non–PCI-capable facility
ould be triaged to fibrinolytic therapy or immediate transfer
r PCI. This decision will depend on multiple clinical
servations that allow judgment of the mortality risk of the
EMI, the risk of fibrinolytic therapy, the duration of the
mptoms when first seen, and the time required for transport
a PCI-capable facility (3). If primary PCI is chosen, the
tient will be transferred for PCI. If fibrinolytic therapy is
osen, the patient will receive the agent(s), and a judgment
to whether the patient is high risk or not will be made. If
gh risk, the patient should receive appropriate antithrom-
tic therapy and be moved immediately to a PCI-capable (Scility for diagnostic catheterization and consideration of
I. If not high risk, the patient may be moved to a
I-capable facility after receiving antithrombotic therapy or
ay be observed in the initial facility.
Patients best suited for transfer for PCI are those STEMI
tients who present with high-risk features, those with high
eeding risk from fibrinolytic therapy, and patients pres-
ting late, that is, more than 4 hours after onset of symp-
ms. The decision to transfer is a judgment made after
nsideration of the time required for transport and the
pabilities of the receiving hospital (2,5). Patients best suited
r fibrinolytic therapy are those who present early after
mptom onset with low bleeding risk. After fibrinolytic
erapy, if the patient is not at high risk, transfer to a
I-capable facility may be considered, especially if symp-
ms persist and failure to reperfuse is suspected.
The duration of symptoms should continue to serve as a
odulating factor in selecting a reperfusion strategy for
EMI patients. Although patients at high risk (e.g., those
ith congestive heart failure, shock, and contraindications to
brinolytic therapy) are best served with timely PCI, “inor-
nate delays between the time from symptom onset and
fective reperfusion with PCI may prove deleterious, espe-
ally among the majority of STEMI patients at relatively low
sk” (p 1299) (81). Accordingly, each community and each
cility in that community should have an agreed-upon plan
r how STEMI patients are to be treated. This includes
hich hospitals should receive STEMI patients from emer-
ncy medical services units capable of obtaining diagnostic
CGs, management at the initial receiving hospital, and
ritten criteria and agreements for expeditious transfer of
tients from non–PCI-capable to PCI-capable facilities (82).
The development of regional systems of STEMI care is a
atter of utmost importance (83,84). This includes encour-
ing the participation of key stakeholders in collaborative
forts to evaluate care using standardized performance and
ality improvement measures, such as those endorsed by the
CC and the AHA for ACS (85). Standardized quality-of-
re data registries designed to track and measure outcomes,
mplications, and adherence to evidence-based processes of
re for ACS are also critical: programs such as the National
ardiovascular Data Registry ACTION Registry, the AHA’s
et With The Guidelines” quality improvement program,
d those performance-measurement systems required by the
int Commission and the Centers for Medicare and Medic-
d Services (86–89). More recently, the AHA has promoted
“Mission: Lifeline” initiative, which was developed to
courage closer cooperation and trust among prehospital
ergency services, and cardiac care professionals (90). The
aluation of STEMI care delivery across traditional care-
livery boundaries with these tools and other resources is
perative to identify systems problems and to enable the
plication of modern quality improvement methods, such as
x Sigma, to make necessary improvements (70,91–93) .
. Recommendations for Intensive Glucose
ontrol in STEMI
ee Table 6.) (94–96)
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s detailed in the 2004 STEMI guideline and the 2007
A/NSTEMI guideline revision, randomized trial evidence
pported the use of insulin infusion to control hyperglyce-
ia (3,97). A recently published randomized clinical trial of
tensive versus conventional glucose control in critically ill
tients raised uncertainty regarding the optimal level to
rget when achieving glucose control. NICE-SUGAR, a
rge, international randomized trial (n6104) of adults
mitted to the intensive care unit with either medical or
rgical conditions, compared intensive glucose control (tar-
t glucose range 81 to 108 mg/dL) with conventional
ucose control (to achieve a glucose level less than 180
g/dL, with reduction and discontinuation of insulin if the
ood glucose level dropped below 144 mg/dL) (16). Time-
eighted glucose levels achieved were 11518 mg/dL in the
tensive glucose control group versus 14423 mg/dL in the
nventional glucose control group. The risk of death was
creased at 90 days in the intensive glucose control group by
6% (27.5% versus 24.9%; odds ratio 1.14; 95% CI 1.02 to
08; P0.02; number needed to harm38). The result
mained the same after adjustment for potential confounders.
here were significantly more episodes of treatment-related
poglycemia in the intensely managed group (6.8% versus
5%, P0.001), although the contribution of hypoglycemia
excess mortality is uncertain (94,98). Overall, the hospital
urse and proximate causes of death were similar in the 2
oups. Excess deaths in the intensive-control group were
edominantly due to cardiovascular causes (absolute differ-
ce 5.8%; P0.02). More patients in the intensive-control
oup than in the conventional-control group were treated
ith corticosteroids.
Because NICE-SUGAR enrolled critically ill medical and
rgical patients, the degree to which its results can be
trapolated to the management of patients with STEMI is
clear. Although recent data from a small, mechanistic
inical trial (28,29,98) suggest that glucose control may
ble 6. Recommendations for Intensive Glucose Control in STEM
04/2005/2007 Recommendations:
04 STEMI Guidelines 2009 Joint STEMI/PC
C
An insulin infusion to normalize blood glucose
is recommended for patients with STEMI and
complicated courses. (Level of Evidence: B)
Cla
1. It is reasonable to us
and maintain glucose
avoiding hypoglycem
a complicated or unc
of Evidence: B)
During the acute phase (first 24 to 48 hours)
of the management of STEMI in patients with
hyperglycemia, it is reasonable to administer
an insulin infusion to normalize blood glucose
even in patients with an uncomplicated
course. (Level of Evidence: B)
*There is uncertainty about the ideal target range for glucose necessary to aduce inflammation and improve left ventricular ejectionaction in patients with acute myocardial infarction (AMI),
hether it will improve patient outcomes remains uncertain.
A consensus statement by the American Association of
linical Endocrinologists and the American Diabetes Asso-
ation (99) summarized that “although hyperglycemia is
sociated with adverse outcomes after AMI, reduction of
ycemia per se, and not necessarily the use of insulin, is
sociated with improved outcomes. It remains unclear,
wever, whether hyperglycemia is a marker of underlying
alth status or is a mediator of complications after AMI.
oniatrogenic hypoglycemia has also been associated with
verse outcomes and is a predictor of higher mortality” (p
20) (99).
There is a clear need for a well-designed, definitive random-
ed trial of target-driven glucose control in STEMI that has
eaningful clinical end points to determine glucose treatment
resholds and glucose targets. Until such a trial is completed,
d based on the balance of current evidence (99–101), the
riting group concluded that it was prudent to change the
commendation for the use of insulin to control blood glucose
STEMI from a Class I to a Class IIa recommendation (Level
Evidence: B) and to recommend treatment for hyperglycemia
eater than 180 mg/dL while avoiding hypoglycemia.
. Recommendation for Thrombus Aspiration
uring PCI for STEMI
ee Table 7.)
d Update Recommendations Comments
Recommendation is no longer current.
See 2009 Class IIa
recommendation #1.
ulin-based regimen to achieve
less than 180 mg/dL while
atients with STEMI with either
ted course (16,94–96). (Level
New recommendation
Recommendation is no longer current.
See 2009 Class IIa
recommendation #1.
an optimal risk-benefit ratio.
ble 7. Recommendation for Thrombus Aspiration During PCI
r STEMI
09 Joint STEMI/PCI Focused Update
commendation Comments
Class IIa
Aspiration thrombectomy is reasonable for
patients undergoing primary PCI (17,18,102).
(Level of Evidence: B)
New recommendationI
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lass I
ss IIa
e an ins
levels
ia* for p
omplica
7.
Si
up
pu
cl
gi
an
as
ba
th
pl
pr
cl
m
th
(P
cu
re
di
ca
no
w
in
ev
th
PC
m
P
70
in
co
at
as
al
(1
ST
ro
th
ve
th
no
tio
su
th
th
is
he
br
th
8
in
(S
8.
Pr
fo
an
de
do
12
pa
w
St
no
pa
ex
in
pu
do
tr
in
co
th
(1
tr
ty
fo
Ta
20
20
1.
ris
endatio
2222 Kushner et al. JACC Vol. 54, No. 23, 2009
2009 Focused Updates: STEMI and PCI Guidelines December 1, 2009:2205–411. Thrombus Aspiration
nce the publication of the last STEMI and PCI focused
dates, 2 new trials of manual thrombus aspiration have been
blished. TAPAS was a single-center, unblinded, randomized
inical trial that compared 2 catheter-based reperfusion strate-
es in 1071 patients with STEMI (17,102). Before coronary
giography, patients were randomized to manual thrombus
piration before PCI (55.1% by direct stenting, 28.6% by
lloon angioplasty followed by stenting, 10.1% by PCI without
rombus aspiration) or conventional PCI with balloon angio-
asty followed by stenting. BMS were implanted in 92% of PCI
ocedures. All patients were treated with ASA, 600 mg of
opidogrel, UFH, and abciximab unless contraindicated. TIMI
yocardial blush grade 0 or 1 occurred in 17.1% of patients with
rombus aspiration and 26.3% of those with conventional PCI
0.001). Complete resolution of ST-segment elevation oc-
rred in 56.6% and 44.2%, respectively (P0.001). Death,
infarction, and TVR rates at 30 days were not significantly
fferent (6.8% versus 9.4%) (17). However, at 1 year, rates of
rdiac death (3.6% versus 6.7%, P0.02) and cardiac death or
nfatal reinfarction (5.6% versus 9.9%, P0.009) were lower
ith thrombus aspiration. Low myocardial blush grade and
complete ST-segment resolution were associated with clinical
ents (102).
EXPIRA was a smaller (n175) randomized clinical trial
at also compared thrombus aspiration with conventional
I, but only in patients with TIMI flow 0/1 (18). TIMI
yocardial blush grade of 2 or more (88% versus 60%,
0.001) and 90-minute ST-segment resolution greater than
% (64% versus 39%, P0.001) occurred more frequently
the thrombus aspiration group. Infarct size measured by
ntrast-enhanced magnetic resonance imaging in 75 patients
3 months was significantly reduced only in the thrombus
piration group.
Both of these trials, as well as a meta-analysis by Bavry et
(103) and a large pooled analysis of randomized trials
04), support the use of aspiration thrombectomy for
EMI. In developing a recommendation for the role of
utine aspiration thrombectomy, however, it is noteworthy
at TAPAS was a study of routine thrombus aspiration
ble 8. Recommendations for the Use of Stents in STEMI
04/2005/2007 Recommendations
2
Cla
1. It is rea
BMS fo
Evidenc
Cla
07 PCI Guideline Update, Table 16
A DES may be considered for clinical and anatomic settings
in which the effectiveness/safety profile appears favorable
but has not been fully confirmed by clinical trials. (Level of
Evidence: C)
1. A DES
settings
favorab
*Consideration for the use of stents (DES or BMS) in STEMI should include the
k in patients undergoing chronic oral anticoagulation, and the possibility that
†For example, small vessels, long lesions, or diabetes mellitus. This recommrsus no thrombus aspiration rather than a study of routine byrombus aspiration versus selective thrombus aspiration. It is
t known whether a strategy of selective thrombus aspira-
n in patients with a large thrombus burden might be
perior to no thrombus aspiration or equivalent to routine
rombus aspiration. Clinically, it is reasonable to assume
at this strategy can be useful in STEMI patients with short
chemic times and large thrombus burden. It may not be
lpful in STEMI patients with long ischemic times, side
anches with small infarct territories, or lesions with low
rombus burden.
. Recommendations for the Use of Stents
STEMI
ee Table 8.) (105–109)
1. Stent Selection for STEMI
imary PCI is generally the preferred reperfusion strategy
r patients with STEMI (110). Compared with balloon
gioplasty, routine BMS implantation during primary PCI
creases risk for TVR and possibly reduces MI rates but
es not reduce mortality rates (111,112).
Two-year data from the Massachusetts registry (113) from
21 propensity score–matched pairs of DES and BMS
tients demonstrated a reduction in mortality and TVR rates
ith DES in primary PCI, and an analysis from the New York
ate registry (114) found a reduction in mortality rates but
t TVR rates with DES. These reports were limited to
tients treated before 2005, so they represent the earliest
perience with DES, in which selection bias may have
fluenced stent choice and off-label use may have been
rsued more cautiously. Additionally, duration of clopi-
grel therapy was longer in the DES group.
More recently, several relatively small randomized clinical
ials have shown an inconsistent efficacy for DES over BMS
primary PCI. Three meta-analyses of these trials have
ncluded that there were no differences in death, MI, or stent
rombosis rates, but TVR rates were decreased with DES
15–117). Variably included were 12 studies that differed in
ial design, inclusion criteria, end-point definitions, stent
pes, duration of clopidogrel treatment, and type of
llow-up (angiographic versus clinical). They were limited
t STEMI/PCI Focused Update
Recommendations Comments
to use a DES as an alternative to a
y PCI in STEMI (11,105). (Level of
New recommendation
considered for clinical and anatomic
ich the efficacy/safety profile appears
109). (Level of Evidence: B)
Modified recommendation (level of
evidence changed from C to B).
f the patient to comply with prolonged dual-antiplatelet therapy, the bleeding
ient may need surgery during the ensuing year (28).
n applies to primary and nonprimary PCI patients with STEMI.009 Join
ss IIa
sonable
r primar
e: B)*
ss IIb
may be
† in wh
le (106–
ability o
the patsample size and duration of follow-up and by usually
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hich may have underestimated its true incidence.
The HORIZONS-AMI trial randomized, in a 3-to-1 ratio,
06 patients to DES or BMS (9,68,105). There was no
fference in the 12-month composite safety end point of
ath, reinfarction, stroke, or stent thrombosis. The rates
ischemia-driven TVR and target-lesion revasculariza-
on were significantly lower in the DES group (5.8%
rsus 8.7% and 4.5% versus 7.5%, respectively; NNT33
1 year), as was the 13-month binary restenosis rate
0.0% versus 22.9%).
In summary, there appears to be no difference between
MS and DES in mortality or MI rates and no difference in
ent thrombosis risk. The major advantage of DES over BMS
a small reduction in TVR rates. Given cost considerations,
could be argued that selective use of DES to prevent
stenosis and TVR in high-risk patients (i.e., patients with
abetes) and in high-risk lesions (longer and smaller-
ameter stents) could be recommended (118), as it has been
r elective PCI. The greatest challenge in selecting patients
r DES implantation, however, is determining in an emer-
ncy situation whether the patient is a candidate for pro-
nged thienopyridine therapy. As with elective procedures,
ES should be avoided in the presence of financial barriers to
ntinuing prolonged dual-antiplatelet therapy, social barriers
at may limit patient compliance, or medical issues that
volve bleeding risks or the need for invasive or surgical
ocedures in the following year that would interrupt anti-
atelet therapy.
CI Focused Update Section
. Recommendation for Angiography in
atients With Chronic Kidney Disease
ee Table 9.)
1. Angiography in Patients With Chronic
idney Disease
tients with chronic kidney disease (CKD) with or without
abetes who undergo angiography are at high risk for a
ntrast-induced nephropathy (CIN). At issue is the selection
a contrast agent to minimize this risk. The 2007 UA/
STEMI guideline recommended that in patients with
ronic kidney disease undergoing angiography, “isosmolar
ntrast agents are indicated and are preferred (Level of
vidence: A)” (p e112) (97). In patients with CKD or CKD
d diabetes mellitus who are undergoing angiography,
ble 9. Recommendation for Angiography in Patients With Chro
04/2005/2007 Recommendation:
07 PCI Guidelines Update, Table 9 2009 P
C
In chronic kidney disease patients undergoing
angiography, isosmolar contrast agents are
indicated and are preferred. (Level of Evidence: A)
1. In patients with
who are not un
contrast medium
low-molecular-w
iohexol is indicaosmolar contrast material was shown to lessen the rise in theatinine. This was based on evidence up to mid-2007 that
ggested that isosmolar agents also reduced the risk of CIN
both a moderate-sized randomized clinical trial (RE-
OVER [Renal Toxicity Evaluation and Comparison Be-
een Visipaque (Iodixanol) and Hexabrix (Ioxaglate) in
tients With Renal Insufficiency Undergoing Coronary An-
ography]) that compared iodixanol with ioxaglate (119) and
meta-analysis of 16 smaller, earlier clinical trials (120).
However, in mid-2007, a major US randomized trial of
ntrast agents in patients with CAD and an estimated
omerular filtration rate of 20 to 59 mL/min who were
dergoing angiography, the CARE study, was published.
ARE compared the low-osmolar agent iopamidol and the
osmolar agent iodixanol and found no difference in the
imary end point (serum creatinine increase of 0.5 mg/dL or
gher over baseline) between iopamidol (4.4%) and iodixa-
l (6.7%, P0.39) (19).
Since then, several larger randomized trials have been
blished that reported no difference in CIN when iodixanol
as compared with various other low-osmolar contrast media
OCM) (19,121–123). These and other randomized trials
mparing isosmolar iodixanol with LOCM have been sum-
arized in 2 mutually supportive and complementary meta-
alyses involving 16 trials in 2763 patients (124) and 25
ials in 3260 patients (125), respectively. When more recent
ials were combined with the older studies, trends in CIN
voring iodixanol were no longer significant (summary RR
79; 95% CI 0.56 to 1.12; P0.29; summary RR 0.80; CI
61 to 1.04; P0.10, respectively) (124,125). However,
banalyses showed variations in relative renal safety by
ecific LOCM: A reduction in CIN was observed when
dixanol was compared with ioxaglate, the only ionic LOCM
R 0.58, CI 0.37 to 0.92, P0.02 (124)), and with iohexol,
nonionic LOCM (RR 0.19 to 0.38, P0.01) (124,125), but
difference was noted in comparisons of iodixanol with
pamidol, iopromide, or ioversal (124), and a single trial
vored iomeprol (123). A pooled comparison of iodixanol
ith all nonionic LOCM other than iohexol indicated equiv-
ent safety (RR 0.97; CI 0.72 to 1.32, P0.86) (125).
esults were consistent regardless of ancillary preventive
erapies (hydration, acetylcysteine), route of administration
ntravenous or intra-arterial), age, sex, dose, or preexisting
KD or diabetes. Of further interest, findings were similar in
e 8 studies (n1793 patients) performed in the setting of
ronary angiography (124).
These more recent observations indicate that the CIN risk
contrast media cannot be attributed to osmolarity alone, but
ney Disease
sed Update Recommendation Comments
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ggests that the recommended choices of contrast media
ring coronary angiography be expanded to either isosmolar
edia or LOCM other than ioxaglate or iohexol.
0. Recommendations for Use of Fractional
low Reserve
ee Table 10.)
.1. Fractional Flow Reserve
oronary angiography is often performed in clinical situa-
ns in which preprocedural functional testing has not been
tained. Additionally, in the setting of multivessel disease,
e need to treat individual stenosis is often difficult to
termine. Although revascularization of ischemia-producing
sions improves patient outcomes, the clinical benefits of
vascularization of stenotic but non–ischemia-producing le-
ons are less clear. Intraprocedural assessment of the func-
nal significance of individual stenosis may help define the
timal revascularization strategy.
The objective of the FAME trial (20) was to compare clinical
tcomes after PCI on the basis of conventional angiographic
termination of lesion severity versus fractional flow reserve
FR) combined with angiography in patients with multivessel
sease. This prospective, randomized, multicenter trial included
05 patients selected from 1905 screened patients at 20 medical
nters who were randomized to either angiography-guided or
R-guided (for lesions with FFR less than or equal to 0.80)
I. Before randomization, lesions that required PCI were
especified on the basis of the angiographic appearance. Pa-
nts assigned to angiography-guided PCI had all identified
sions treated with DES, whereas those assigned to FFR-guided
ble 10. Recommendations for Use of Fractional Flow Reserve
04/2005/2007 Recommendation:
05 PCI Guideline, Section 5.6.2. 2009 PCI Fo
Cla
It is reasonable to use intracoronary physiologic
measurements (Doppler ultrasound, fractional
flow reserve) in the assessment of the effects of
intermediate coronary stenoses (30% to 70%
luminal narrowing) in patients with anginal
symptoms. Coronary pressure or Doppler
velocimetry may also be useful as an alternative
to performing noninvasive functional testing
(e.g., when the functional study is absent or
ambiguous) to determine whether an
intervention is warranted. (Level of Evidence: B)
1. Coronary pressure
velocimetry can b
specific coronary
velocimetry can a
performing noninv
functional study is
whether an interv
use intracoronary
pressure FFR [2
Doppler velocimet
assessment of the
stenoses (30% to
anginal symptoms
Cla
Routine assessment with intracoronary
physiologic measurements such as Doppler
ultrasound or fractional flow reserve to assess
the severity of angiographic disease in patients
with a positive, unequivocal noninvasive
functional study is not recommended. (Level of
Evidence: C)
1. Routine assessme
measurements su
ultrasound to asse
concordant vascul
a positive, unequi
recommended. (LeI had only identified lesions with an FFR of 0.80 or less afeated with DES. The primary end point of the trial was the rate
death, nonfatal MI, and repeat revascularization at 1 year.
No difference was evident in the number of intended
sions to be treated per patient (2.70.9 versus 2.81.0,
0.34) in the angiography- and FFR-guided groups, respec-
ely. In the FFR group, 37% of lesions had an FFR greater
an 0.80. Evaluation of ischemia, as defined by an FFR less
an 0.80, resulted in fewer lesions receiving stents (2.71.2
rsus 1.91.3, P0.001). At 1 year, the composite event
te was 18.3% in the angiography-guided group compared
ith 13.2% in the FFR-guided group (P0.02).
The results of the FAME trial suggest that identification of
chemia-producing lesions by use of systematic assessment
FFR in patients undergoing multivessel PCI is associated
ith improved clinical outcomes compared with angio-
aphic assessment alone. Further evidence is needed regard-
g the added value of assessing FFR in lesions with greater
an 90% stenosis.
1. Recommendations for PCI for
nprotected Left Main Coronary Artery
isease
ee Table 11.)
.1. Unprotected Left Main Coronary Artery Disease
lthough listed as a Class III indication in the 2003 guideline
the management of chronic stable angina (145), PCI of an
protected left main coronary artery has increased in fre-
ency (146). Early studies (listed in Appendix 6) involved
ort follow-up periods, which gave CABG a disadvantage,
cause the apparent benefits of surgery over PCI in other
ttings have not typically been fully evident until 1 to 5 years
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December 1, 2009:2205–41 2009 Focused Updates: STEMI and PCI Guidelinesdate for PCI, the performance of PCI for left main CAD is
ven a Class III, Level of Evidence C recommendation if the
tient is eligible for CABG and a Class IIa, Level of
vidence B recommendation for patients who are not eligible
r CABG. Thus, it has been recommended that CABG still
considered the standard of care for left main CAD
47–149).
Several studies comparing CABG to PCI, however, indi-
ted that the advantage of CABG consists primarily of fewer
peat revascularizations (139,149 –155). The study by
rener et al (156) indicates no significant mortality difference
tween PCI and CABG after 3 years of follow-up. Longer-
rm follow-up is needed.
The present focused update specifically addresses the
ndings of SYNTAX, an unblinded, randomized clinical trial
at assigned patients with 3-vessel and/or left main CAD to
initial treatment strategy of CABG or PCI (21). The
imary prespecified end point for the 1800 enrolled patients
as the composite of death, stroke, and myocardial revascu-
rization determined at 12 months. Prespecified stratification
curred for diabetes mellitus and left main CAD. Ninety-
ven percent of CABG patients received at least 1 arterial
aft.
In SYNTAX, for the subgroup with left main CAD, there
ere no significant differences in the incidence of the
mposite end point (death, MI, stroke, or repeat revascular-
ation) between the 2 groups (PCI 15.8% versus CABG
.7%, P0.44), although rates of repeat revascularization
ble 11. Recommendations for PCI for Unprotected Left Main C
04/2005/2007 Recommendation 2009 PCI Focuse
Cla
05 PCI Guideline, Section 6.3.4.
It is reasonable that patients undergoing PCI to
unprotected left main coronary obstructions be
followed up with coronary angiography
between 2 and 6 months after PCI. (Level of
Evidence: C)
Cla
1. PCI of the left main
alternative to CABG
with anatomic cond
low risk of PCI proc
conditions that pred
surgical outcomes (2
Cla
05 PCI Guideline, Section 5.1
PCI is not recommended in patients with . . . 
f. Left main disease and eligibility for CABG.
(Level of Evidence: C)
05 PCI Guideline, Sections 5.2, 5.3
PCI is not recommended in patients with . . . 
e. Left main disease and eligibility for CABG.
(Level of Evidence: C)
*Stenting for unprotected left main CAD is relatively more favorable for patie
gle-vessel disease (21), for patients with ostial or mid left main coronary arter
ior thoracic surgery, or poor bypass graft targets) that would make CABG
protected left main CAD may be relatively more favorable for patients with lef
ions (138,140–144), or low surgical risk with a good chance of technical suere higher (11.8% versus 6.5%, P0.02) and rates of stroke mere lower (0.3% versus 2.7%, P0.01) in the PCI group
1). Left main stented patients with limited CAD (lower
NTAX score) displayed a trend toward fewer adverse events
12 months than did similar patients assigned to CABG.
ecifically, MACE in patients with isolated left main CAD
curred in 8.5% with CABG versus 7.1% with PCI, and in
.2% with CABG versus 7.5% with PCI in patients with left
ain CAD and disease of 1 other vessel. In contrast, MACE
ith CABG versus PCI were numerically less frequent in
tients with disease of the left main coronary artery and
sease of 2 other vessels (14.4% versus 19.8%) and in
tients with both left main CAD and 3 other vessels
volved (15.4% versus 19.3%) (21).
These data from a post hoc subgroup analysis in SYNTAX
ust be interpreted with caution for several reasons. The number
patients with isolated left main (or left main plus single
ssel) CAD was relatively small, and the differences in out-
mes were not statistically significant. Furthermore, SYNTAX
ported outcomes at 1 year, and longer follow-up is needed
fore left main PCI (in patients who are otherwise surgical
ndidates) should become standard clinical practice. Moreover,
cause the overall study did not reach its primary end point,
bset analyses are less robust; because noninferiority was not
oven in this cohort, specific information for each subgroup is
an observational nature and is hypothesis-generating.
On the basis of the evidence in aggregate, prior to and
ithin the present focused update, the writing group has
y Artery Disease
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Deleted recommendation (no longer
recommended).
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complications and clinical
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39).* (Level of Evidence: B)
New recommendation
Modified recommendation (bullet “f” from
Section 5.1 and bullet “e” from
Sections 5.2. and 5.3. are no longer
current; see 2009 Class IIb
recommendation #1).
isolated left main coronary artery lesions or left main coronary artery plus
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evel of Evidence as B. The writing group noted 3 important
veats in classifying unprotected left main CAD as a Class
b indication. First, patients undergoing PCI in cohort or
ndomized studies represent merely a subset of all patients
ith left main CAD. Because only certain left main coronary
sions are amenable to PCI, the Class IIb indication is
tended to apply only to those left main lesions that are
itable for PCI. The primary conclusion of SYNTAX is that
I failed to be shown to be noninferior to CABG in left
ain and triple-vessel disease. Because patients in SYNTAX
ith left main and 2- or 3-vessel disease compared with
tients with left main and no other vessel or 1-vessel disease
d higher rates of MACE, it is recommended that PCI to
ft main lesions be limited to patients without significant
ultivessel disease. Second, because of the narrow margin
r error, operators undertaking PCI of left main coronary
sions should be experienced and backed by highly
mpetent support staff and surgeons (157). Although
utine use of intravascular ultrasound has been advocated
some authors for the evaluation of left main lesions,
ere is no definitive evidence at present that this technique
proves outcomes (138,157). Finally, not all left main
sions respond equally well to PCI. Bifurcation lesions are
chnically more challenging (138) and have higher rates
restenosis (140,141,143,144). In contrast, results of PCI
ostial or mid-body left main coronary lesions more
osely approximate the results of CABG, even with
spect to the need for subsequent procedures (142). The
st case for PCI as an alternative to CABG for left main
AD is in ostial and mid-body lesions without additional
ultivessel disease.
The writing group discussed the previous Class IIa recom-
endation for follow-up between 2 and 6 months with
ronary angiography. They focused on the inability of
giography to predict a situation that might be prone to
ute, sudden stent thrombosis, as well as the risk associated
ith angiography in a patient who has undergone placement
a left main stent. In view of these factors, the writing group
cided that the Class IIa recommendation for angiographic
ble 12. Recommendations for the Timing of Angiography and
04/2005/2007
commendation 2009 PCI Focused Upd
C
1. Patients with definite or likely UA/NSTEMI selected
dual-antiplatelet therapy (158,159). (Level of Evide
(158,159). (Level of Evidence: A) Clopidogrel (befo
Evidence: A) or prasugrel (at the time of PCI) (27)
antiplatelet agent.
Cla
1. It is reasonable for initially stabilized high-risk pat
Acute Coronary Events risk score greater than 14
to 24 hours of admission. For patients not at high
(22,23). (Level of Evidence: B)
*Immediate catheterization/angiography is recommended for unstable patientllow-up should be omitted from the guidelines. C2. Recommendations for the Timing
f Angiography and Antiplatelet Therapy
UA/NSTEMI
ee Table 12.)
.1. Timing of Angiography
routine invasive strategy in UA/NSTEMI patients with
gh-risk features has been associated with improved out-
mes, but the optimal timing of intervention has not been
ell established. Early intervention might prevent ischemic
ents that could occur while the patient awaits a delayed
ocedure. Alternatively, with intensive antithrombotic ther-
y with a delay for up to a few days, procedure-related
mplications might be avoided by intervening on a more
able, “passivated” plaque. Although one study has sug-
sted greater benefit with relatively early intervention (106),
e evidence base for a definitive recommendation on timing
weak. Thus, the question of when to intervene in UA/
STEMI has not been answered conclusively. Given this
certainty, the TIMACS investigators (23) undertook a
rge, multicenter randomized trial to determine whether a
rategy of early coronary angiography and intervention was
perior to a delayed strategy in patients with UA/NSTEMI
signed to an invasive approach.
TIMACS randomly assigned 3031 non–ST-elevation ACS
tients to routine early intervention (coronary angiography
ithin 24 hours) or to delayed intervention (coronary angiogra-
y at 36 hours or more). The primary outcome was the
mposite of death, MI, or stroke at 6 months, and a prespecified
condary outcome was death, MI, or refractory ischemia (23).
Coronary angiography was performed at a median of 14 hours
the early-intervention group and 50 hours in the delayed-
tervention group. At 6 months, 9.7% of patients in the
rly-intervention group experienced a primary outcome versus
.4% in the delayed-intervention group (HR 0.85; 95% CI 0.68
1.06; P0.15). Death, MI, or refractory ischemia was reduced
28% in favor of early intervention (9.6% versus 13.1%; HR
72; 95% CI 0.58 to 0.89; P0.002). Prespecified analyses
owed that early intervention improved the primary outcome in
e one third of patients at highest risk (HR 0.65; 95% CI 0.48
0.88), as determined by a GRACE (Global Registry of Acute
telet Therapy in UA/NSTEMI
mmendations Comments
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December 1, 2009:2205–41 2009 Focused Updates: STEMI and PCI Guidelinesirds at low to intermediate risk (HR 1.14; 95% CI 0.82 to 1.58;
for heterogeneity0.01). There were no safety issues related
early intervention; major bleeding occurred in 3.1% of
tients in the early invasive group and 3.5% in the delayed
vasive group.
Overall in TIMACS, early intervention trended to be
perior to delayed intervention in preventing the composite
death, MI, or stroke (primary end point), but the difference
as not statistically significant (23). However, early inter-
ntion reduced the composite of death, MI, or refractory
chemia (the secondary end point) and, in high-risk patients,
as superior to a delayed invasive strategy. The trial was
derpowered to discern a clinically meaningful 15% advan-
ge to early invasive therapy for the primary end point, with
cruitment stopped at 3000 because of recruitment and
nding challenges. This provided a power of 80% to detect
risk reduction of 28% in the primary end point. Subgroup
alysis (high-risk subset) of this overall negative trial was
t robust and must be viewed cautiously.
Taken together with the earlier ISAR-COOL (Intracoro-
ry Stenting With Antithrombotic Regimen Cooling Off)
udy (106), the favorable secondary end-point results, the
bgroup analysis in patients at higher risk, and the lack of a
fety issue with early therapy, TIMACS suggests the fol-
wing conclusions: an early invasive strategy within 12 to 24
urs (median 14 hours) is preferred in high-risk patients and
ay be chosen in patients at low to intermediate risk at the
ysician’s or institution’s preference (e.g., efficiency and
st savings), whereas a more delayed approach may be
neficial in low- to intermediate-risk patients (23). In
ntrast, results from the recent ABOARD (Angioplasty to
lunt the rise Of troponin in Acute coronary syndromes
andomized for an immediate or Delayed intervention) trial
60) indicate that an immediate invasive strategy (median
e 1.1 hour) in UA/NSTEMI is not associated with further
cremental benefit.
Typically, early versus delayed angiography is defined
ith reference to a 12- to 48-hour time window. The
AR-COOL study (106) supports an earlier compared with a
ore delayed time to angiography, but the data supporting
is general timing suggestion are limited.
.2. Timing of GP IIb/IIIa Receptor Antagonist Therapy
UA/NSTEMI Patients Undergoing Angiography
he optimal timing of initiation of GP IIb/IIIa receptor
tagonist therapy in patients with UA/NSTEMI (i.e.,
hether to administer therapy upstream on presentation or
ter at the time of angiography/PCI) and the optimal appli-
tion of this therapy (i.e., whether routine, selective, or
ovisional) have not been resolved. The 2007 ACC/AHA
uidelines for the Management of Patients With UA/
STEMI recommend that patients with definite or likely
A/NSTEMI selected for an invasive approach should re-
ive ASA and either clopidogrel or a GP IIb/IIIa receptor
tagonist before angiography (Class I, Level of Evidence:
) (97). They further state that it is reasonable to initiate both
opidogrel and a GP IIb/IIIa receptor antagonist, especially
the setting of delays to angiography, high-risk features, or adcurrent ischemic discomfort (Class IIa, Level of Evidence: B).
he 2007 European Society of Cardiology guidelines recom-
end early dual-antiplatelet therapy with ASA and clopidogrel
lass I), with the addition of a GP IIb/IIIa receptor antagonist
r those patients with the specific high-risk features of an
evated troponin level, ST-segment depression, or diabetes
lass IIa) (163).
The EARLY ACS (Early Glycoprotein IIb/IIIa Inhibition in
tients With Non–ST-Segment Elevation Acute Coronary Syn-
ome) trial (22) tested the hypothesis that a strategy of early,
utine administration of the GP IIb/IIIa receptor antagonist
tifibatide would be superior to delayed, provisional adminis-
ation in reducing ischemic complications among high-risk
tients. EARLY ACS enrolled 9492 non–ST-segment eleva-
n ACS (UA/NSTEMI) patients who presented within 24
urs of an episode of ischemic rest discomfort and who were
signed to an invasive treatment strategy no sooner than the
xt calendar day (amended later to at least 12 hours but less
an 96 hours after randomization). Eligibility required at least 2 of
e following features: ST-segment depression or transient ST-
gment elevation, an elevated biomarker (creatine kinase-MB or
ponin), and age of 60 years or older (amended to include patients
to 59 years with known vascular disease). The key primary end
int was all-cause death, MI, recurrent ischemia that required
gent revascularization, or thrombotic bailout at 96 hours. The key
condary efficacy end point was all-cause death or MI within 30
ys. Safety end points included major hemorrhage and transfu-
ons through 120 hours after randomization. The study was
wered to detect 22.5% and 15% relative reductions in the primary
d key secondary end points, respectively.
The primary end point occurred in 9.3% of patients in the
rly therapy arm versus 10.0% of patients in the provisional
P IIb/IIIa therapy arm (odds ratio 0.92; 95% CI 0.80 to 1.06;
0.23). Secondary end-point event rates were 11.2% versus
.3% (odds ratio 0.89; CI 0.79 to 1.01; P0.08). Early,
utine eptifibatide administration occurred at the cost of a
eater risk of TIMI major hemorrhage (2.6% versus 1.8%,
0.02). Moderate and less severe bleeding also occurred
ore commonly. Rates of red cell transfusion were 8.6% and
7%, respectively (P0.001).
EARLY ACS represents a large, carefully executed trial with
tentially important implications; however, these results are
st taken in the context of previous major trials. As a single
ial, EARLY ACS does not establish the superiority of early
rsus delayed, provisional eptifibatide in non–ST-elevation
CS. A trend toward fewer recurrent ischemic complications
as noted at 30 days, but this was counterbalanced by more
equent episodes of bleeding and need for transfusions. Given
e use of eptifibatide at PCI (39% of patients in the delayed,
ovisional group), EARLY ACS does not contradict the benefit
GP IIb/IIIa therapy over placebo in UA/NSTEMI in previous
udies. Rather, its findings relate specifically to the timing of
ch therapy and selective versus routine use.
In another similar study, ACUITY (Acute Catheterization
d Urgent Intervention Triage strategY), superiority of early
P IIb/IIIa therapy also was not found, but investigators
uld not exclude as much as a 29% benefit with GP IIb/IIIa
erapy nor show noninferiority of delayed administration. In
dition, drug exposure before angiography was much shorter
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r differential efficacy (161).
The results of the EARLY ACS study are similar to a
eta-analysis of 6 prior large, randomized trials of GP IIb/IIIa
erapy versus placebo in non–ST-elevation ACS in which an
vasive strategy was not mandated, which showed a relative
duction in death/MI of 9% (CI 2% to 16%) (162). In those
tients who underwent PCI, the RR reduction was a more
bust 23% (CI 8% to 36%). This finding also was consistent
ith EARLY ACS. Both studies found no benefit in troponin-
gative patients. The investigators ascribed the less than ex-
cted benefit of early GP IIb/IIIa therapy in EARLY ACS to
nvergence of eptifibatide use in the 2 arms at the time of PCI
d more aggressive contemporary cotherapies compared with
rlier studies, including frequent use of clopidogrel, low-
olecular-weight heparin, and statins. A further caution is the
ck of follow-up for several years.
Despite a lack of clarity from the overall and subgroup
sults, an argument can be made against the routine upstream
e of GP IIb/IIIa therapy in all non–ST-elevation ACS
tients intended for an invasive strategy. In particular, those
ith a normal baseline troponin level and those over the age
75 years, in whom there was no evidence for benefit but
ho showed an increased risk of bleeding, might be ex-
uded. On the other hand, findings in those with a positive
oponin at baseline and those with diabetes, although not
finitive in EARLY ACS alone, trend positively and are ine with previous results. The EARLY ACS trial showed no
gnificant benefit in the composite outcome comparing early
rsus delayed eptifibatide as defined by the study. Thus, at
is time, a high-risk group that would clearly benefit from
e early administration of eptifibatide upstream before car-
ac catheterization has not been identified. Early GP IIb/IIIa
erapy in patient groups continues to appear reasonable if
ey are judged clinically to be at high risk of thrombotic
ents relative to bleeding risk.
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During PCI
Comments: All Patients to Receive
ASA (162–325 mg)ug*
Patient Received Initial Medical
Treatment (With an
Anticoagulant and/or
Fibrinolytic Therapy)
Patient Did Not Receive Initial Medical
Treatment (With an Anticoagulant
and/or Fibrinolytic Therapy)
ycoprotein IIb/IIIa Receptor
tagonists (Section 2)
Abciximab Of uncertain benefit LD of 0.25 mg/kg IV bolus
MD of 0.125 mcg/kg per minute
(maximum 10 mcg/min) (Class IIa,
LOE: A)
Continue for up to 12 hours at the
discretion of the physician (9,11).
Eptifibatide Of uncertain benefit LD of 180 mcg/kg IV bolus followed 10
minutes later by second IV bolus of
180 mcg/kg
MD of 2.0 mcg/kg per minute, started
after first bolus; reduce infusion by
50% in patients with estimated
creatinine clearance 50 mL/min
(Class IIa, LOE: B)
Double bolus recommended to support
PCI in STEMI as the recommended
adult dosage of eptifibatide in
patients with normal renal function
(6,7).
Infusion should be continued for 12 to
18 hours at the discretion of the
physician (9).
Tirofiban Of uncertain benefit LD of 25 mcg/kg IV bolus
MD of IV infusion of 0.1 mcg/kg per
min; reduce rate of infusion by 50%
in patients with estimated creatinine
clearance 30 mL/min (Class IIa,
LOE: B)
Increased dosing over previous
recommendation (11,12).
Continue for up to 18 hours at the
discretion of the physician (12).
ienopyridines (Section 3)
Clopidogrel† If 600 mg given orally, then no
additional treatment
A second LD of 300 mg may
be given orally to
supplement a prior LD of
300 mg (Class I, LOE: C)
LD 300–600 mg orally
MD of 75 mg orally per day (Class I,
LOE: C)
Optimum LD has not been established.
Dose for patients 75 years of age
has not been established.
There is a recommended duration of
therapy for all post-PCI patients
receiving a BMS or DES.
Period of withdrawal before surgery
should be at least 5 days.
(For full explanations, see footnote.)
Prasugrel‡ No data are available to guide
decision making
LD of 60 mg orally
MD of 10 mg orally per day (Class I,
LOE: B)
There is no clear need for treatment
with prasugrel before PCI.
MD of 5 mg orally per day in special
circumstances.
Special dosing for patients 60 kg or
75 years of age.
There is a recommended duration of
therapy for all post-PCI patients
receiving a DES.
Contraindicated for use in patients
with prior history of TIA or stroke.
(For full explanations, see footnote.)
renteral Anticoagulants
ection 4)
Bivalirudin For patients who have received
UFH, wait 30 minutes, then
give 0.75 mg/kg bolus, then
1.75 mg/kg per hour
infusion (Class I, LOE: B)
0.75 mg/kg bolus, 1.75 mg/kg per hour
infusion
Bivalirudin may be used to support PCI
and STEMI with or without
previously administered UFH with
the addition of 600 mg of
clopidogrel (9). In STEMI patients
undergoing PCI who are at high risk
of bleeding, bivalirudin
anticoagulation is reasonable (9).
(Continued)
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During PCI
Comments: All Patients to Receive
ASA (162–325 mg)ug*
Patient Received Initial Medical
Treatment (With an
Anticoagulant and/or
Fibrinolytic Therapy)
Patient Did Not Receive Initial Medical
Treatment (With an Anticoagulant
and/or Fibrinolytic Therapy)
UFH IV GP IIb/IIIa planned: target
ACT 200–50 seconds
No IV GP IIb/IIIa planned:
target ACT 250–300
seconds for HemoTec,
300–50 seconds for
Hemochron (Class I, LOE: C)
IV GP IIb/IIIa planned: 50–70 U/kg bolus
to achieve an ACT of 200–50
seconds
No IV GP IIb/IIIa planned: 70–100 U/kg
bolus to achieve target ACT of
250–300 seconds for HemoTec,
300–50 seconds for Hemochron
(Class I, LOE: C)
ACT indicates activated clotting time; BMS, bare-metal stent; CABG, coronary artery bypass graft; DES, drug-eluting stent; GP, glycoprotein; IV, intravenous; LD,
ding dose; LOE, level of evidence; MACE, major adverse cardiac events; MD, maintenance dose; PCI, percutaneous coronary intervention; STEMI, ST-elevation
yocardial infarction; TIA, transient ischemic attack; and UFH, unfractionated heparin.
*This list is in alphabetical order and is not meant to indicate a particular therapy preference. This drug table does not make recommendations for combinations
listed drugs. It is only meant to indicate approved dosages if a drug is chosen for a given situation.
†The optimum LD of clopidogrel has not been established. Randomized trials establishing its efficacy and providing data on bleeding risks used an LD of 300 mg
ally followed by a daily oral dose of 75 mg (26,27). Higher oral LDs such as 600 mg or more than 900 mg (36) of clopidogrel more rapidly inhibit platelet aggregation
d achieve a higher absolute level of inhibition of platelet aggregation, but the additive clinical efficacy and safety of higher oral LD have not been rigorously
tablished. For post-PCI patients receiving a DES, a daily MD should be given for at least 12 months unless the risk of bleeding outweighs the anticipated net benefit
forded by a thienopyridine. For post-PCI patients receiving a BMS, an MD should be given for a minimum of 1 month (28) and ideally up to 12 months (unless the
k of bleeding outweighs the anticipated net benefit afforded by a thienopyridine; then it should be given for a minimum of 2 weeks). The necessity for giving an
of clopidogrel before PCI is driven by the pharmacokinetics of clopidogrel, for which a period of several hours is required to achieve desired levels of platelet
ibition. Patients who have a reduced-function CYP2C19 allele have significantly lower levels of the active metabolite of clopidogrel, diminished platelet inhibition,
d a higher rate of MACE, including stent thrombosis (53). In STEMI patients taking clopidogrel for whom CABG is planned and can be delayed, it is reasonable to
continue the clopidogrel to allow for dissipation of the antiplatelet effect, unless the urgency for revascularization and/or the net benefit of clopidogrel outweighs
e potential risks of excess bleeding. The period of withdrawal should be at least 5 days in patients receiving clopidogrel (30). Clopidogrel LD after fibrinolytic therapy:
r patients given fibrin- and non–fibrin-specific fibrinolytic drugs who are undergoing PCI within 24 hours, 300 mg; for patients given a fibrin-specific fibrinolytic
dergoing PCI after more than 24 hours, 300 to 600 mg; for patients given a non–fibrin-specific fibrinolytic undergoing PCI between 24 and 48 hours, 300 mg; for
tients given a non–fibrin-specific fibrinolytic undergoing PCI after 48 hours, 300 to 600 mg.
‡Patients weighing60 kg have an increased exposure to the active metabolite of prasugrel and an increased risk of bleeding on a 10-mg once-daily MD. Consider
ering the MD to 5 mg in patients who weigh 60 kg. The effectiveness and safety of the 5-mg dose have not been studied prospectively. For post-PCI patients
ceiving a DES, a daily MD should be given for at least 12 and up to 15 months unless the risk of bleeding outweighs the anticipated net benefit afforded by a
ienopyridine. Do not use prasugrel in patients with active pathological bleeding or a history of TIA or stroke. In patients 75 years of age, prasugrel is generally
t recommended because of the increased risk of fatal and intracranial bleeding and uncertain benefit, except in high-risk situations (patients with diabetes or a
tory of prior MI) for which its effect appears to be greater and its use may be considered. Do not start prasugrel in patients likely to undergo urgent CABG. When
ssible, discontinue prasugrel at least 7 days before any surgery. Additional risk factors for bleeding include body weight 60 kg, propensity to bleed, concomitant
e of medications that increase the risk of bleeding (e.g., warfarin, heparin, fibrinolytic therapy, or chronic use of nonsteroidal antiinflammatory drugs).
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*Time since onset of symptoms; risk of STEMI; risks associated with fibrinolytic therapy; time required for transport to a skilled PCI laboratory.
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ference, Year Type of Study, Years of Recruitment PCI/CABG Short-Term Results Long-Term Results
ieffo et al (141), 2006 Cohort, 2002–4 107/142 In-hospital outcomes for PCI versus CABG:
Death: 0% versus 2.1%; PNS
MI: 9.3% versus 26.1%; P0.0009
Stroke: 0% versus 2%; PNS
1-Year adjusted ORs for PCI versus CABG:
Death or MI: 0.26; 95% CI 0.078–0.597; P0.0005
Death, MI, or stroke: 0.385; 95% CI 0.180–0.819;
P0.01
Revascularization: 4.2; 95% CI 1.486–14.549; P0.005
e et al (151), 2006 Cohort, 2003–5 50/123 30-Day outcomes for PCI versus CABG:
Death: 2% versus 5%; PNS
MI: 0% versus 2%; PNS
Stroke: 0% versus 8%; P0.03
Death/MI/stroke/revascularization: 17%
versus 2%; P0.01
1-Year follow-up for PCI versus CABG:
Death: 4% versus 15%; P0.2
Death, MI, stroke: 4% versus 21%; HR4.4; 95% CI
1.0–18.6; P0.03
Revascularization: 13.3% versus 5.5%; P0.2
lmerini et al (152), 2006 Cohort, 2002–5 157/154 30-Day outcomes for PCI versus CABG:
Death: 3.2% versus 4.5%; PNS
MI: 4.5% versus 1.9%; PNS
Revascularization: 0.6% versus 0.6%;
PNS
1- to 2-Year follow-up for PCI and CABG:
Death: 13.4% versus 12.3%; 95% CI 0.51–1.77;
P0.8
MI: 8.3% versus 4.5%; 95% CI 0.21–1.32; P0.17
Revascularization: 2.6% versus 25.5%; 95% CI
0.03–0.23; P0.0001
szman et al (150), 2008 Randomized, 2001–4 52/53 30-Day outcomes for PCI versus CABG:
Death: 0% versus 0%
MI: 2% versus 4%; PNS
MACE: 2% versus 14%; 95% CI
0.79–0.99; P0.03
1-Year follow-up for PCI versus CABG:
Death: 2% versus 8%; PNS
MI: 2% versus 6%; PNS
Revascularization: 30% versus 10%; 95% CI
1.05–1.54; P0.01
MACE: 32% versus 26%; 95% CI 0.85–1.38; PNS
(Continued)pendix 5. Triage and Transfer for PCI
Angio indicates angiography; CABG, coronary artery bypass graft; Cath Lab, catheterization laboratory; LOE, level of evidence; PCI, percutaneous coronary
ervention; and STEMI, ST-elevation myocardial infarction.
Each community and each facility in that community should have an agreed-on plan for how STEMI patients are to be treated that includes which hospitals should
ceive STEMI patients from emergency medical services units capable of obtaining diagnostic electrocardiograms, management at the initial receiving hospital, and
itten criteria and agreements for expeditious transfer of patients from non–PCI-capable to PCI-capable facilities. Consideration should be given to initiating a
eparatory pharmacological regimen as soon as possible in preparation for and during patient transfer to the catheterization laboratory. The optimal regimen is not
t established, although published studies (see text for details) have used various combinations of the following: anticoagulant, oral antiplatelet agents, intravenous
tiplatelet.
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